Annual Report incorporating a Dirertors. Report and Accounts for the year ended 31 December 2023 theeve appeal Gynaecology Cancer Research Fund Annual Report and Accounts for the year ended 31 Decefflber 2023 Company Reglstratlon Number. 04370087 Registered Charity Number {ErvAlaThd and Wales): I1708 Re$tel•d Charity Number {ScOda. SCIJ42612
Annual Report incorporatlng a Dlrectors. Report and Accounts for the year ended 31 December 2023 Content5 Le8al and Administratlve Infonnatlon................................................................................................-... From the Chalr of Trustees..................................................................................-..-..-............... .- -...... From the Chlef Executlve....... Planning for the year ahead- Putting Preventkn rst.... Objects and Artlvitle&.... Achievements and Perfornwnce.................................-.................-....-.....-..-..........-...... .10 .12 .13 Structure, Governance and Managemert.....-.....-......-....-.....-....-.-..........-....... .....-. Financial Review 2023.....-....-....-.........-..-....... .-..... ....-....-.-...-... . .28 -33 Statement of Tru5tee5' Re5pon5ibifrtie5...... Independent Auditorf5 ReporL..--....-.-....-.-....-......-.......-...-..-....-.-....-....- Consolidated Statement of Financial Actlvitles foryear ended 31 December 2023............................41 Consolldated and Chartty Balan Sheet as at 31 December 202*... ..4Z Consolldated Statement of Cash Flows for the year ended 31 December 2023..-....-...........-.-...... Notes to the Financial Statements... -.36 ..43 ..44
Annual Report incorporating a Dlrertor< Report and Accounts for the year ended 31 Decernber 2023 Legal and Administrative Information Charity Nan Gynaecolo8y Cancff Research Fund- operatlng as Yhe Eve Appeal, Trustees Tamara Box (Appointed oU07n020) (Chair of Trustees effective 0810212024) (Appointed IWlln019) (Appointed 29109noffi) (Appointed 26iion020) (Appointed 29105n022) IAppolnted 19IIV2019) IAppolnted 27iion021) IAppointed 04/lln019) IAppolnted 2qIO/2020) IAppolnted 18IIOn023) IAppolnted 18/ion023) (Appointed 18no/2023) Sarah aark lan Drew Dr Christlne Ekechl Dr lan Jacobs Sarah Morrfs Marion Hara Cathy PltthaTrWHey Dr Adam Rosenthal Sally Bailey Dee Brecker Emma Dean Chlef Executlve Athena Lamnisos Reglstered Charlty Number IEn8land and Wale51: I1708 Reglstered Charlty Number (Scotland): SC042612 Reglstered Company Numbw: 04370tM7 Principal ¢)ffl¢e of Charfty and Reglstered Olftce The Eve Appeal 10-18 Unlon Stree( London. SEI ISZ Audltar Moore Kln85ton &nith LLP, 6th Aoor. 9 Appold Street. London. EC2A 2AP Banker5 CAF Bank Llmlted. 25 Klngs Hlll Avenue. Klngs Hill. West Mallln& Kenl ME19 4JQ
Annual Report incorporating a Dirertor< Report and Accounts for the year ended 31 December 2023 Unlty Trust Bank pl4 PO Box 7193. Planetary Road. Wlllenhall. WVI 9DG Solkitors 8ates We115. 10 Queen Street Pla. London. EC4R IBE Reed Smfth. 8road8ate Tth¥er. 20 PrFmrose SL London EC2A 2RS
Annual Report Incorporating a DlrectOT< Report and Accounts for the year ended 31 December 2023 From the Outgoing Chalr of Trustees A Legary of DfiCatIen and Impxt: A Futwe Hlled Hope Dear Supporters and Frfends of The Eve Appeal. As I pen this annual report. I do 50 wlth a wofound sense of wlde and gratitude, reflectlng on the remarkable Jour we have undertaknn together at The Eve Appeal. It ha5 been an honour to serve as a Board member for the past 14 years and as the Chalr of the Board of TN5tee5 of The Eve Appeal since 2019. In 2023. we celebrate not just the culmlnation of arnther impactfvl year but a150 the launch of a tran5forniative initiative- our Fellowship Scheme. Thi5 forward-thinkin8 program 5i8nifie5 our commitment to inve5tin8 in re5earth Stars of thE future. fosterin8 innovation, and en5urinB the lon8evity of our missi( to erdthats 8ynaecolo8ical cancer5. The FelkhIP Stheme Is a testament to our dedication to the next Beneration of researchers who will undoubtedly lead us to new frontiers In the fight aBalrs1 these devastatin8 dtseases. Our cornmltment to 1ftvatIon and strategic partnerships continues to be a cornerstone of our success. By leverallng collaboratlve efforts and thlnklng creatl¥ely. we contlnue to maxlmlse the Impact of our research fundin& enablife US to support groundbfeaking wojects and initiatives. We are thrilled to be worfrtin8 Wlth the medical research charlty, North West Cancer Research. 8y co- fundlng the fellowshlp scheme. we have the opportunlty to provlde the transfomiatlonal support that researthers need to make Impact. This appn>ath not only amplifies our reath but also paves the way for sustalned prn8ress In 8ynaecob8ical cancer re5earth. The challenglng economlc cllmate of recent times has tested our re*fRnce. but l am pleased to report that we have weathered the stomi. In the face of adverslty. we have remalned steadfast, demon5tratinE the true impact of our work and the critical need for our mission. By stickin8 ts a clear stratw and effectively mana8in8 risks. we have navi8ated thro¥h a uniquely challen8in8 time, emerging stronger and more deterrnined than ever. We want to share our thanks to our wonderful donors and partners wlM> have helped u5 meet our fundraisin8 objertlves In the past year. We are arateful for thelr contlnued sUPPOrt. None of what we achieve would be possible without each and every one of our donors and strategic partners and thelr continuing effort5 and generogty. It is important to recoBni5e the dedication and ambition of our incredible staff team under the excellent IEadEr5hip of our Chief Executive. Athena. Their fvHs5ion, dili8ence. and commitment are the driving force behind every succes5 we celebrate today. A brilliant example vf this dedicatiun is
Annual Report Incorporatlng a Dlrectors. Report and Accounts for the year ended 31 December 2023 our Ask Eve Coordlnator. Helen. who received an MBE in the New Years Honours list. Despite a significant Increase In callers to our gynae health Infomiation seNice, and the thaHen8es she faces with managing her own treatment for womb cancer. Helen's unwaverlng commltment has provided a lifeline for so many wrKnen wlth Sae health concern& To Helen. and to each member of The Eve Appeal famity. l extend my deepest gratltude foryour tlreless efftirts and steadfast bellef In our shared mission. As I step down from my role as ChaFr of the Board of Trustees. I do so with immense prlde In what we have accompltshed together. The Eve Appeal is not just a researth charity. it is a communlty united by a common goal. I have every confidence that we will continue to break barriers, drive Innovation, and make strlde5 towards a fvture Whe gynaecological an¢er5 are a thlng of the past. Thank you, from the bottom of my hearL for be6n8 part of thls InuedSble Journey. Our collective impact is a beacon of hope for countle55 Indivlduals affected by the 8ynaecolo8kal cancers. I'm very proud of our legacy and ho for the future.'I know that under the In518htful 5tewardshlp of the new chalr, Tamara Box, w•th our bnlliant board, team and world class researchers, we will make powerful strlde5 forward In 2024. Wlth slncere gratitude, Melanie Richards CBE. Outgoing Chalr
Annual Report incorporating a Director< Report and Accounts for the year ended 31 December 2023 From the Chief Executive Rlsln8 Above the Chalknges As we reflect on the past year. it ts imp(ible to IBnore the unparalleled thallen8es: for those affected by heatth canm5. for The Eve Appeal. and for Society. We contlnue to see the overwhelming pre55ure on the NHS and 8ynaecolo8y services. The tlrele55 efforts of our medlcal advocates have been stretched to their limits a5 they grnpple with the backlog of cases, Wlth patients often waiting many weeks for crucial diagnostic tests. This wait extends significantly for those in areas Wlth limited access to 8ynaecolo8ical oncolo8Y 5UPPOrt or speo'alist women'5 health 5ervice5. Our focus at Evels on prevention and earty d5agnosls. We know that when dlagn0515 cornes late, the prognos15 15 often much poorer. Our Ask Eve nurse information services has never been more needed for those waiting and worryin& One of the most pressmig challenges confrontls the aring Inequality in research furnllng wlth 50 lfftle available for 8¥ncOlo£lCal cancers. The disproportionate 8kal investment In prostste nCer research Is strlkln& Perpetuat1 a sV5temic imbalart that knes gynaecologlcal cancer re5earth Severely underfunded. The consequen5 of this fvfidi 8ap are deeply felt In our ability to mak? strldes In the prevention. earty detection. and trealment of 8ynaecologKal cancers. Cornparatlve analyses of global investment in cancer research reveal an alarmin8 trend where women dlsproportlonately lose OUL The glari disparltles In fundlr are not merely financlal but translate into lf-Erfe consequences for women Brappllrq with 8ynae¢olo8ical health concerns. The detrimental Impact of this dlscrepancy is evldent across variou5 fronts. from research Initiatives to publlc awareness campa*ns and a£sSIble healthcare. The consequences of th15 underfnvestment are acutely felt by wornen dlasnosed wlth naeCO1081ca1 cancers, as they confront not only the physical and emotional toll of the dlsea5e but also the 5y5temic neglert In re5earth and healthcare infrastructure. ft Is dlsheartenin8 to Wit$5 the d15parlty In outcomes when compared to cancers that ceIve mwe substsntial finandal supwL We are working to break thls cyde of Inequallty In women's health. We corrtinue to advocate for in¢rea5ed awareness. understandin& and, m05t irnportantty. e4Uitable fvnding for Bynaecological cancer research. We will contlnue to Push for increased investment, foster collaboratlons. and champlon research Inltlati¥es that aim to tran5forrn the landscape of gynaecological cancer research. We know that to reath our ambltlons we need to work in partnership. DurinB 2023 Eve continued our powerful work In many coalition5 including One Canr Voice. Cancer52 and the new HPV Coalftlon. We also fast-foFwarded a new strategy to fund research in partnership with other charltles - effectlvely doubllng the investment into 8ynaecolo8ical cancer research. We are 50 proud of the
Annual Report incorporating a Director< Report and Accounts for the year ended 31 December 2023 Impact that our Fellowshlps partnershlp with North West Cancer Researth will bring to the most carnmon 8ynaecolo8iol Gincer. womb cancer. We are proud to have supported 8roundbreaking research such as Martln Wldschwendterfs work on the WID test. rnarkin8 a signfficant step forward in our mission. Creatlng klnder, more speclfic and more equitable diagnostic tests Is core to our mlsslon. Make Screen1r better for women. This early test for womb cancer could create a Step chanse. SeelnB Professor Ranjlt Manchanda's work on population test5ng for BRCA gene mutations manifest into a natian-wide screening programme via the NHS was a defining Moment for the charlty. Research funded by Eve proved the clinical efficacy of thts programme In 2016. Our research paper demonstrated that rollln8 screenlr8 oiit to hlgh rtsk populatlons Thild save WA more lives. It is fanta5tlc to See thls malnstreamed Sn the NHS In 2024. In the future. we vuld like our findin85 to 8et to the cllnlcal settin8 laster. Thanks to the gener055ty of our Incredtble supporters. our Rare Gynae Cancer Fund continues to grow. The first two project5 awarded in 2022 got started in eame5t this year, and Professor Sudha Sundarfs project on muanous ovarian cancer has already received two significant pots of follow-on funding, We ran our Second Rare Gynae Cancer call, and we look forward to announc1 detalls of the award in the nearfuture. We are equally dellghted to welcome Dr. Kelechl Nloku as our Inaugural Eve Fellow. and his support his search for a kinder. siffler test to detett endometrial cancer. Or. NJoku'5 dedlcatlon exempllfles our commltment to advanclng knowled8e and findlng 6nnovatlve solutlons. Our partnership with North West CarKer Research extended to support the co-fundlng of a second ftllowship, and this call launched In eath 2023. DespSte the limlted resources and perslstent challenges. our outreath and enga8ement program5 contlnue to make a Mean11 Impact. The You Need to Knovk Campalgn, tallored for Black women to recogniie the red fla8 symptoms of womb cancer. has proven especially impartful. Addressin8 the alarming ststiStic that black women are 2 times more likely to succumb to womb cancer. th15 Inltlatlve alms to brldge the Bap In awarene55 and empower women to take control of their health. As we naviBate this everryevolvin8 landscape. we extend our heartfelt Brntitude to our out8oin8 Chalr of Trustees. Melanie Richards CBE. for her invaluable leadership. We warmly welcorne Tamara Box as our new Chair. confident in her ability to lead The Eve Appeal into the next chapter of our mlsslon. Heartfelt thanks also Bo to Profe550r lain McNeish, Chair of our Re5earth Advisory Comrnittee. We've had the pleasure of having Profe550r lain McNei5h leadin8 our RAC for the last six years- we could not have been tn rrK>re capable and insighthil hand5. laln ts a leadinB light in the field of 8vnaecological cancer researclL He has brilantlY sUPPOrted our Board In keeping the focus on our mlssion and research strategy. 20Z3 has been a particularty excitin8 year as we have developed a new fellowshlp scheme and open research calls in rare gynaetological cancers. Our new programme wlll bulld the gynaecolo8ical cancer research stars of the future. We extend our awjreciation to the entire Eve community for thelr unwaverin8 SUPPOrt and dedlcatlon to our cause. To8ether. we wlll contlnue to make strkles in the preventlon. early
Annual Report Incorporatlng a Dlrertors. Report and Accounts for the year ended 31 December 2023 detection, and screening of Bvnae Canrs. and continue reachin8 out to those in need with 5UPPOrt and information to support 8ynaecolo8ical health. Our is fuelled by phllanthropy and the zenerosity of so many. Athena Lamni505. CEO
Annual Report incorporatlng a Dlrectors, Report and Accounts for the year ended 31 December 2023 Planning for the year ahead- Putting Preventlon First Worklng wlth a range of stakeholders. Eve launched a 3wear strately in 2023. Our mission fff 2023- 202515 to be here for everyone affected by gynaeco1lcal cancers- to provide them with Information. amplify awareness, drive education. iwire support for the cause and fund world<lass research to transfom? earty diwosis and prevention of these diseases. Thi5 IS the area of cancer re5earth with the deepest fundin8 gap and the 8reatest potentlal to prevent the immeasurable costs of treatir¥ late•StaBe disease. We are the only national tharfty to focus all our efforts on wevention. funding WOrtd4lass research and prograrnmes to ralse awareness of sl8ns symptoms and risk facto across all five cancers. We will achieve our vlslon- a future Bynaecologl&il cancers are dlsea5e5 of the pa5t- thmugh our 51n8le-mlnded focus across all our programmes on earfy dlagnosis, risk pdICtIon and prevention of these cancers. We believe that every slngle case of canw that can be prevented should be, and 5rKlude everne In our work Goals 2023-25 Invest in innovation and d15¢0very We wlll unlock new and better ways to under5tsnd gynae Canr. thro seed-fvndlnB Innovatlon and moonshot research programmes. We wlll explore new avenues to fvnd our researchers. Indudlnz cornmerclal opportunities that arise from research. We WMI streamline the way we work and engage to help athieve our mi5510n. Ensage and translate We will accelerate our researth fin&in85 into clinkal practk4 by sharfng impact with the broadest range of policy. publlG academ14 Ived*xperlence and cllnlcal stakeholders. We wlll seek out those who need access to our heath inforniation and ensure it is shared In a way that Is accessible and relevant to them. Drlve 5UPPOrt lor our vision throryh colaboration We will work across disciplines. across boundaries. and connect In meanlnBful ways with all of Dur new and existing stakeknldefs, wlth the alm of ralslng the funds ne£essary to achieve our mlsslon. Priorities & Plans A5 a medlcal research charfty and an expert health information wovlder. we need to understand IrRquallt5es wlthln health and researth are many and variedl and make addresslng these. part of everything we do. This cornmltment underplns our charltable actfvltles 2024 and beyond. We are prtydresslng our ambltSws agenda through unprecedented challen8e5 and durirw a time of economlc uncertalnty re5uItFnE from Blobal events The impacts on health services have been hu8e and thls has provlded u5 with challen8es but also opportunitie5- to pivot our pro8ramrne work onllne. form excltlng partner5hip5 and thereby reach more people with our service io
Annual Report Incorporatln8 a Directors. Report and Accounts for the year ended 31 December 2023 Our prforltk5 for 2014 Research & Provldlnz Expert Infornmtion Corrtlnue to advocate for fundln8 af 8ynae cancers amorq5t the scientific research community, highllghtlng the need for addftlonal fundin8 to enable rfsk prediction and earty detection. by engaging and leading committees and steerfn8 groups. and wotkin8 cbselv wlth Poli makers and government where posslble. To supm t vi51on of The Eve Appeal through raising in exc£5s of El.3rn in cost-effective ways. alllwlng u5 to support our research programmes. our Ask Eve nurse-led Informatlon servlce. and our education awarene55 and Informatlon campai8ns. To devebp fvrther partnerships with research ch3rltles In the sector to fund collaboratlve programmes and fellOlp& Work c105ely and collatrA>ratively with fellow member5 of the Association of Medical Research Charlties lo Make the case for investing in medical researth and the impact that this achieves. 155ue an osyen call durin8 2024 in the core strateglc areas of fellowshlp. Contlnue to market the Ask Eve Serv1 a5 the 'zo to. charlty for expert Infonnatlon and 5i8npostln£ on all five gynaecologlcal cancers: vrith a particular focus on signs. 5ymptom5. risk factor5 and preventbon. Maklr the seThlce aSSIble to all wlth a focus on those with the highest barriers to accesslnz health Inforniatk and screenlng seNlces. Prlorltlsing developing resour5 for groups disproportionatety affected by health inequalltle5 and where needs are currently unmeL Extendin8 our reach Build our European and international research networks thrnugh stskeholder work and attendlng and leadlng international conferences and events whlch focus on naecOlogICal cancer prevention. Extend our Ask Eve service thro fvrther consolklation and formallsatlon of our partnershlps wlth a dlverse range of community. patient and peer organisations that work directly wlth convnunltles dlsswoportlonatsly affected by 8ynaecological cancers, and in areas where there are slgnffint gaps In Infomiatlon provlslon. Launch Ir Eve Volces, collaboratxm in Autumn 2024 for Gynaecological Cancer Awareness Month. To reach more commurnties In the workplace by s18nln8 up both larger organlsatlons and SMES to our Every Wornan Promise 8ynaecological health at Wofk initiative Contlnue to bulkl The Eve Appears brand and reputation as an authoritative voice on all matter5 In relatlon to 8ynaecological cancefs and thek sl£ns and symptoms. through targeted awarene55 campagns for the public, cllnical and relevant policy audiences. A rw webslte will be launched during the summer whlch WHI work to meet all our sUPPOrter needs. li
Annual Report Incorporating a Dlrector< Report and Accounts for the year ended 31 December 2023 Bulldlr¥ a strong team to meet Ouf arnblllon Meet the ambitious tsrgets set out in 2024 financial year which build on leamlw from 2023 succes5e5. The plans demonstrate our commitment to a knsL learn, Implemeny approach and support dS8ltal Innovatknn across our fundralslng StaM5 and fDCUS on the development of our major glfts programme. Thls Is crltlcal In meetlng the needs of our research rtrategy and bulldln8 new fundlng streams for fellowshlps through new relatlonships wlth prlvate donors. trusts and foundations. Consolldate the new govemance strtureS wlthin the Board of Trustees, ar support continued functioning of the Finance and Audit Committee, Research Committee and the Development Board. Continue embedding equity. diversity and inclusion worwan across all our activity. focusin8 on co-production and w01n8 with patients and other8roups to ensure that everythln8 we produce meets the need5 of the communftle5 who would benefit from our Infomiatton arKI servlces. Complete the revlDn of al ?rP1aCe policie5 and procedures (from cyber security to enhanced parental leave) and roll out training to all staff. This will ensure the team is 5UPPOrted and can operate effectNety. and ensu that the charity 15 operatin8 to best practice in all area5. Publlsh our impact rewt In Sumw*r 2024 whkh brfngs togetherthe monitorin& evaluation and impact data that we have gathered acr055 proyamme5 and Bynaecolo8ical cancer research and unmet need. We be8ln 2024 and the new financial year in a stawe but cautioUY optimistic positlon, intently focused on contlnuln8 ourvltal ffl1ss5on and wlth a deaf plan for what we need to achieve over the next two year Object5 and Activities Introduction Orfglnally founded as the Gynaeco108y Cancer Research Fund in 1984 by Professor lan Jacobs, The Eve Appeal was establtshed In 2CQ2 to ia55e awareness and funds Into the researth of the five synaecoloBical cancers: womb. ovarfan. cervlcal. vulval and ¥38lnal. Every day In the UK. 60 women are diagnosed with a gynaecological cancer and 21 WMI die. Impro¥ln8 these grim ststistics will take targeted investment in preverrtative research, but only 5% of UK cancer fvndln8 research goes on prevention and a tlny percentage of the total on the 8ynaecologlcal cancers. One In three people can't name a Bynae canr and one In four have felt not listened to In a gynae health appDlntment . The Eve Appeal was set up to save yeS by fvnding ground-breaking research. since 2015 we've awarded over £3ffl to re5ear¢h focused on developlng new $cenIn& risk Preittl0n and ear detectlon methods. The research we fund Is ambltlous and challengin& whlle our razor-sharp focus means our fundlng leverages further fundlng from other sources. Alongside research. we also ralse I W(Yfd C•w RESearth Fund 12
Annual Report Incorporating a Dlrector< Report and Accounts for the year ended 31 December 2023 vltal awareness of slgns and symptoms. break down taboos and stlllma. and offer a free nurse-led Information seryice. where anyone can ask anythin& The case for investing in KynaecoloKital cancer research has never been more needed. As a research chaiity, we are proud to have been able to continue our research Impact by investing new funds this year and not pau51n8 or reducing any previously awarded research fund& Gynaecology Ginr Research Fund. tradlng as The Eve Appeal. Is a company Imited by guarantee and a reglstered charity. In Its fflemorandurn and articles of assodatlon (last updated 2 February 2022), the Charitys objects are outlined a5 follow5: To advance and fund research 5nto gynaecologlul caKers and disseminate the rEsuIts of such research; To advance public educatlon and thereby raise the proflle and awareness of Eynaecologlcal cancers, and thelr slgns and symptoms. rfjk fartors lincludin8 8RCA and inherited ri5k51; To relieve the nd5 of women affected by the gynaecolo8lcal cancers. and inherited rlsk factors lincludin8 8enetK mutations) by wovldinB Inf0mtIon and support seNices for such women. thelr families, friends and health and social care professionals. Aims and objectlves The Eve Appeal is leathng UK national charfty ralslng awareness and fundlnz research into the five 8ynaerolo8ical cancers. The Chaiity was set up to Save Ilves by funding groun&breakln8 researth focused on develowng effective methods of risk prediction, eadler detectSDn and prevention for the gynaecolog5cal cancers. We have played a cnKial role provkllng x%d fvnrfin& CO infrastnthre fundlng and projert ndlnz In addition to campalgnSng to ralse awareness of gynae Caer$. The wortd4eadlr4 researth that fund 15 am1105 and thallerylry but our 75[0 is simple: A futurn where the r¥naeMloel&il cancus are a d15ea5e of the past. Publlc Benefit Statement In report5n8 on the objertlves and achievements of the Charlty. theTStee5 have 8iven due re8ard to the Charlty Comm155lon BUIdan on public benefft under the Charitie5 Art 2011. The Gynaecology Cancer Researth Fund constltutes a public benefrt entity as defined by FRSIO2. Achievements and Performance Research The Eve Appeal contlnues to showthat In the under-proftled field of 8ynaecologkal cancer researth, a small fund focused on early detection, prevention and screening can have great Impact. Increaslngly. more stakeholders- Including govemment, policy and allled charftles- are reco8ni5ing the Importance of preventlng and deterting these cancers before the burden Is great. We continue to 5tr5ve to detect every case of 8ynaecolo8ical cancer as early as posslble. when ft Is most treatable. nd ultimatety prevent thue cancers from developln8 In the first place. 13
Annual Report Incorporating a Dlrector< Report and Accounts for the year ended 31 December 2023 We contlnue to make slgnllScant pro8re55 on our objectlves set In the 2023-2025 organisational strategy: Establish the Eve Appeal Fellowshlp Programme Support earty career researchers from clÈnical and academlc bxkgrnunds Fund research across all five gynaecolo8lcal Canr5 Support our heritage core programmes Strengthen and support the Research Advisory Committee Capture and share impact of research artivity across the organisathn Ensure partnershlp and collaboration with key stakeholders across the research landscape Develop Patnt enBaiement with rese¥th Establlsh The Ew Appd Fellowshlp Pro£rnmme- Support1 eth Qveer re5evthers With limlted fundin& and uncertain pathways. the challen8es far re5earcher5 workln8 In 8ynaecolo8lcal cancer are numerouL A priority for The Eve Appeal is to cont5nue our legacy of Investlng in the next 8eneratlon of 8ynaecolo8Kal cancer research stars. The aim is to attract and retain these re5earther5 in the field. by provldlnB substsntial financial assistance. resources, networK support and opportunlties. By fosteri the expertise and passion of these emerging leader5, we hope to drive adwdncements. Potentially leadin8 to qroundbreakinK discoveries and improved prevention and detection strate8ies. The Eve Appeal has a 2t>year track record of seed fundlng research on screenln8, earty detectkin. preventlon and rlsk predlctlon. We have supported and nurtured the career5 of a series of outstandlng researchers at an earty 5taBe of their career. They have all gone on to secure major programme awarth and have had a major impact In BynaecotO8ical cancer research. Some of the leadin8 researcher5 5UPPOrted by Eve InCIle lan jaco Martln Wldschwendter, Usha Menon, Adam Rosenthal. Ame Lanceky. $5mon Gayther and San Rasmu& After extenslve nSUltatIon wlth a rar8e of allled charlties. researchers and key stakeholders both natlonally and Internatlonally. the fellowship programme w35 launched In May 2023. The scheme was open to exceptlonal researcher5 In UK in5titutlon5. who have the potential to lead their own groups in dlscovery, translatlonal or dlnkal re5earth wlthin the reakn of prevention, risk prediction and early detection of Eynae cancer. Reco8n15ing the track recard of The Eve Appeal and the ImpKt of the projects fvnded over the lart 22 years, North West Cancer Researth- a medical research charity working In the North West of En8land- approached the charfty to Co-fund research projects. As The Eve Appeal was already in the mK4st of the call for applications for the fellowship scheme. a memorandum of under5tandln8 was organised between the two charities to jointly fund th• 2023 fellowship stheme. The total financlal Investment for The Eve Appeal l North West Cancer Research Fellowship was up to £120.000 per vear. to cover salarles and dlrecily incurred costs of research for 3 yea Our revlew processes were constructed in line with 8uldance and 8ovemance conslderation5 set out by the As50Ciatton ol Medical Research Charfties Prfndples of Peer Revlew. In November 2023, we appointed our first Inaugural fellow: Dr Kelechl Njoku from the Unlver55ty of Manchester, who will use hs fellowshlp to deveknp a slmpler and kinder test for detecttn8 womb cancer. There were many Strong applications and hope to see more fantastlc researchers joining Dr Njoku a5 EvelNWCR Fellows In the fvture. We have confidence that The Eve Appeal and North West Cancer Research Fellow5hlp5 will provide a stepchan8e in transforniatln8 Bynae cancer research. and 14
Annual Report Incorporating a Dirertors. Report and Accounts for
the year ended 31 December 2023
achieve our shared Visi of a fijture where the fNe 8yrwecological cancers are efther prevented or
diagnosed at the earliest 5ts8e.
Dr Njoku hape5 to be8in his woject in Summer 2024.
Fund research ac1 all 6ynaeculoEiral ¢an-aCtIVe grdnts 2023
Small Cell Q4arfan Cancer Re£tslry
The Small Cell Ovarlan Cancer Reglstry Is led by Dr Wllllam Foulke5 at McGill University. Montreal. It
is a Collaboratlon between The Eve Appeal. Angela's Fund and researcher5 at Cambridge UnivErsity
and Unlverslty College London. The project alms to develop an International Research Collaboration
and Patlent Registry, con501id*in8 the knowledle and experience of Ix>th patients and cliniclans to
provlde a nece55ary foundation for effectNe research irrto Small cell ovarian cancer.
In 2021 (and as a direct result of early support for project) we were dell8hted to receive news
that the project had been Successful In securins a large Krant of $6(Th from the Canadlan
Department of Defense Rare Diseases Fund to support the projert over several years. Consequently,
we have been able to redirect muth of our committed yant to other vltal research Into rarer ovarian
cancer5.
Dr Foulkes has chan8ed the fuS of the remainln8 Eve Brant and has been awarded a no
Annual Report Incorporating a Dlrectors, Report and Accounts for the year ended 31 December 2023 Increasing awareness ol 8ynaecoloEkal cancer and early detectkni In yaung won*n: Feasibility study of a unlverslty-based educatlonal and behablour chae Intsrvention Or Patrfcla Holsch at Leeds Beckett UnNefsIty Is runnlng a mlxed methods feaslblllty Study to a5S1St In the development of a unIVeIty multl-centre trlal to Sncrease awarene55 of and 5ymptom5 for Bynaecolo8ical cancers. After a delayed start due to Covld and the resultiTra delay wlth ethic5 and recwitment, the study started in Jantsary 2022. The team have secured extra findlng from the Centre of Psychological Research IPsyCen) for addltlonal research asslstant tlme to enable them to complete the prolert after the Covid delays. Ultimatety. the interventkn wlll empower youn8 women to be aware of and Seek help for symptoms of gynaecolo8lcal cancer. Lynth Syndrome Predirtm of Endometrlal Camer ILSP£CI Lynch Syndrome increases the risk of an individual developlng endometrlal Iwomb) cancer, as well as several other carKers. Dr Adam Roserthal at UnerSIty College London Hospital 15 investi8atin8 the hypothesls that mismatch repair (MMR) defects de¥elop in the normal end0triUM. prior to the development of atypical encknietrial hyperplasia IAEH) and/or endornetrial cancer. The team reIVed ethics approval after si8nificant delays and have now stsrted anatysis. This proposed work is essential in developi the dirertion of the research team whlch Is now focusing on endometrial surveillance in v•omen with Lynth Syndrome. HS8h throuihput laser-asslsted Rapld Evaporatkn lonlsatlon Mass Spoctrometry (Laser-AEIMS) In th• earty detertlon and dialnosh of ¥ul¥al precancer and cancer Professor Marfa Kyr8lou 55 uslng technology prevlousty used In Eve fvnded research: the tethnlque15 now belng used for early (ktectlon and dkBnos15 of vulval cancer. The diagnosis of PCanCerOUS and CanrOuS lesions can present difficulties as the <fisease can wesent wfth atyplcal symptoms and lesions that can mimic other skin condltiorth There are many thalle when surglcally treating the dlsease. The technolo8y. called La5er-REIMS. allows Interrogatlon of blolo8lcal saTnples In near-real time without the need for prior sample sryjardtion. During analy515 Wlth laser-REIMS a Sample is rapldly heated with the use of a minimally invasive laser• producing an infonnation-rich vapour. wh5ch can be used to accurately identify whether the tissue is healthy or contsin5 precancen)u51cancerous re8lons. By identifytng these re8lons In real tlme wlthln the gynaecolo8y £lln5c or gratIn1 theatre. doctors can offer an ImmedFate dlagnosls and proceed to further excisional treatment of the dlseased area5 If nece55ary. Maria's alm Is to expand the use of this technology to improve dia8nosls and allow earlier detectlon of raref 8ynaecological dlsease5. 5uth as vulval intraepithellal conditlon5 <VIN) and cancer. charartQnSat o15tsrokl metabolome In mudnous ovarlan cancer Thls proJecL led by the leadlng gynae oncologist Professor Sudha Sundar, aims to Klentify new too for the earller dla8n0515 of mucinous ovarian cancer. This is an extreme rare type of ovarlan cancer whlch when dla8nosed at advanced Sta8 has very few successfvl treatment options. 16
Annual Report Incorporatlng a Directors, Report and Accounts for the year ended 31 December 2023 The team's prevlou5 research investigated urine 5teroKI profiles In healthy WLvnen and women undergoing sur8ery or blopsy for suspected ovarian cancer. This was based on work by Professor Wiebke Arlt in adrenal cancer. where her team estsbli5hed that urine steroid profiles could dlfferentiate accurately between adrenal benlgn tumour5 and adrenal cancer5. The adrenal gland and the ovarfes arise from the same 'ridg¥ of tissue when babies are developing as embryos. In thelr work. rather serendipitously, they Jentlfied that 5 sterold metsbolltes Invohed In the earllest stages of 5terold hormone pr0durtl( were elevated In muclnous cancer and mucinous borderline ovarlan twnour5 compared to healthy Mxnen Iw(wnen with beni8n tumours or other cancer types. In the project, they vRnt to confEnn thelr findings in urine saMe$ collected from a larger set of women under8olng sur8ery for ovarfan masses anatyse urine from wmen with known mucinous ovarian cancer undergolng follow-up and analyse samples from women undergolng surgery for 5U5perted mucinous canr of posslble bowel orfgln. An excellent team have been recruited. and a number of patlent engagement and collaboratlon initiatives are alrEady in place. Fund researth au055 all fN• (ancws-ap•n tall Rare Gynao Cancer Resurth 2013 The second Rare Gynae Cancer Research Call opened in May 2023. with a funding pot available to award was £g0.c.c¥•. A number of stw appllcatlons were recelved from candldate5 around the country. These were revlewed by the Research Advisory Committee (RAC) in September 2023. There were robust external peer revlews for each ol the applications. The RAC unanimously agreed to fund the prct proposed by Dr Jason Yap from the Unlverslty of Blrmlngham. which focuses on dOpla a vulval cancer rbk wedlctlon model based on the cancer field theory In Uchen 5defOSUS. The Eve Appeal are delighted to be supportlnK another projert focused on the under-researched area of vulval canw. Thts projert is due to start In May 2024. Support our heritale wre prvyamme5 A penultlmate research Brant was avrdrded to Professor Martin w1dschdterfS team at University College London to ensure the continued momentum of his EVevSupd portfolio of researth as he works to secure k>ng-term fund1 from other sour. The team's work on the WID•-qEC test for detertknn of womb cancer contlnued. Womb canrIS the 4th m05t common cancer in women and case numbers are Increas1. Womb carKers dlagnosed early are treatable and outcomes a good. 8ut even small delays in dlagnosis Mean that a cancer is likely to be diagnosed at a later stage. The projert team has developed a slmple. quick to proces5, obJective test that detects womb cancer. The test- called the WID•.qEC test was discovered and validated in several sample sets but requlred further Ydlidation in a 'real world. clinlcal 5ettinB. Results of the EPI-SURE study were finalised in June 2023, with excellent results and a publication In Lancet Oncology. The study compared the performance of the team's test wlth rout5ne diagnortlc procedure5, wlth the test performlng veryweN. Implementlng the WID•*EC would slmpllfy and Speed vp diaBnosis for women with womb canw symptoms. 17
Annual Report incorporating a Dlrector< Report and Accounts for the year ended 31 December 2023 Further Investl8atlons Into populatlons who are at Increased risk for womb cancer Ilncludlng black women and those wlth Lynch Syndrome) WMI be Snve5tl8ated thls year. The team have strong patlent and public involvement initiatives. and have ernbedded equality. diversity and inclusion initiatives Into their research plans. In addltlon to the actton polnts set (xrt In the or8anisatlonal strategy. we are contlnualty revlewln8 8overnance mea5ure5 to ensure are In COmlance with AMRC 8uidelines. and In keepin& wlth the chariV5 mi55K¥n and purp05e. In September 2023, the Researth Committee (Rcomm) was established. The comm5ttee fulfils number of important functtons wlthln the charlty. namety: Re5earth strate8y and plannin& focused on 0r8anit10nal threeear prioritle5. TEA 5trate8y and guldelines Revlew researth Inlttaths. Opportunities fty strategic partnerships and collaboration In research Providiryd a55urance about the peer revlew process conducted by the Research Advlsory Committee Ilncl(k4ln8 handlFng any challenges or conflkts of Interest that arfse) Scrutlny of appllcatlon budgets to ensure requests are reasonable Fundin8 and resourcirg for research Translation of impart of TEA-funded rnsearth Monitoring of key research perforrnan indicator8 Ilud¥ the ut1115atlon of fvnds awarded Risk and asxxiated mitigations arising from research activity Re8ulatory obli8ations specifically latsd to researth actifft. Our external review body, Research Advls0ry Committee. recrulted a new Chalr, Emma Cr05bie. Professor of GynaeoJlogic31 Oncolo8y at Manthe5ter University. Enwna ha5 tsken over from I January 2024 after Professor lain McNeish stepped down at the end of 2023. We are dEliBhted that Emma will be leading our Eroup of extemal and lay reviewer& The Eve Appeal are keen to develop member5hlp of the RAC. and this wlll be done wlth Profe550r Crosble leading the process for review by the charlty 8oard. Areas of Inte$t have been outllned, and a shortllst of names are under review. We are grateful to Professor McNetsh for his leadershlp and sUPPOrt over sever31 years and gratefvl to all past and present merntxr5 for their time and commitment Capture and share Impact of resea Ktmty auw•S the owlsatlon The Eve Appeal has a partlcular strenBth in sharin8 researth impart and success with key 5tskeholders and the generdl publiL This is important not only for the researchers who are looklng to build thelr profile, but to build patient engagement with research. and develop researcherf5 chances for follow-on funding and share detsils of thelr researth. It also wovldes our donors and supporters with evidence of the work we are supportln8. In addltlon to sharln8 new5 across a range of platfOrn (Indudlng soclal rnedia, newsletters. with press and publlc relatlons wlth broadcast and re8ional press). the tharity shares impact of research 18
Annual Report incorporating a Directorf Report and Accounts for the year ended 31 December 2023 Investment wlth donors and supporters. We are gathering storfes and Impact data on the range of herttage projerts that The Eve Appeal has supported ¢wer the years. and will be 5harini thi5 in an impact report in Summer 2024. A number of Eve reseaher5 have attended staff meetlngs to share detsi15 of theFr work. Th1515 particularly rneaningful for those not engaged with the research on a dally basls - for example, the fundr415in8 team. Thelr work Is v5tal to the contlnued sUPPOrt of research, arKI this connection between research and fundrai51ng provfdes an imptyknt inspirin8 and engaglna Ilnk to the whole staff team. Ensure prtnehIP and collth)rakn whh key stakththlers acr< the researth landscape Collaborntive working is a key value at The Eve Appeal. and thls ho5 been exernpfified by the partnerships. connections and collaborations developed in 2023. The partnershlp wlth North West Cancer Researth (NWCR) is a key example. Wre after belng approached to ctrfund research. we We able to rapidly engage In a partnershlp to co4und fellowshlps. We levera8ed the connectlon with the Assoclatlon of Medlcal Research Charities. and their partnership focus over 2023. to fadlltate an arraernent whlch draws on the 5trenBth5 of both or8anisations to realise a covetable fellow5hlp stheme. We have worked tO8ether not only on the funding slde. but also on marketln& communicatKW and support. We are delighted to be worklng with NWCR on a second fellowship in 2024. The Eve Appeal ha5 developed a network of allied charities, meetln8 re8ularly to dlscuss thallen8es. opportunities and way5 to collaborate to maxifflise funds available. This connection has facilitsted the 5harin8 of a rdn8e of opportunities and we hope that th15 further manifests into additional iolnt- funded projects in 2024 and beyond. Develop ent eeMert*1th r•s•anh With the focus of fundlnz medlcal research and ratslry awareness through outreath and educatlon. some May argue that patlent Involvement Is less rekvant for The Eve Appeal. Many volces contrfbiAe across the organlsation in ffleaningful ways already (lay members on the Research Adv150ry Commlttee. people sharlnE thelr storles, a bank of medical athiocates who regularly contrlbute. along wlth several estsblished Ambassadors) and there is a stron8 5en5e of community. However, systems for 5UPPOrtin8 these irKlividua15. tracking engaBement and recognising the important role they play within the charity has not been defined. As more people get involved. It Is Important to impart our value5 to tIK who are connected with the tharity. provlde a structured Induction. 5UPPOrt them along their ioumey with the charity. and recoKni5e (and where possible) reward their effor as they us work towards athiev1 our mlsslon. A proposal for meaningful lived experlence engagement wlth researth has been developed after extensive consultation with stakeholders. and we are exclted to consult with the CDmrnunity and Implement a number of these InStlatlve5 In 2024. 19
Annual Report Incorporatlng a Director5. Report and Accounts for the year ended 31 December 2023 Ask Eve- Nur5e-Led Information Service Ask Eve ¢ontlnues to be a lifeline for anyone nrned. dlalnosed. or affected by a 8ynaecolo8ical ncer. enabllng people, from all communltles. to ac55 trusted health advice when thry need It. Wlth on8oln8 wessures on the NHS. the demand for Ask Eve Is rapidly increasin8 alongslde the complexity of contacts. Ask Eve had a 109% increase in contacts over the135t 12 months. Many people with concerns about symptoms, questions about genetic5 arKI who are experiencing significant delay5 In appolntments. Investgatlons. results and treatment contsct Ask Eve for lnl0rniatl. slgnpostln& and support. We contlnue to engage with hundred5 of people. from diverse cixnmunitie5. providin8 Vital Informatlon on Bynaecolo8ical cancers. raising awarene55 of important 5i8n5 and 5ymPtom5, promotin8 earty dia6nosi5. encouraBbnG preventative Ktion for those at risk and 5UPPOrting those dia8n05ed arKI their lovEd one5. at all 5ta8e5 of the pathway. We are dEli8hted to continue to imprrnR the acce55ibility of Ask Eve using both telephone and written interpretatbon seNKe& extendin8 our range of easy read materials and havir¥ access to BSL as required. We now offer access to Ask Eve via an online contact fonn. This is a popular OPtk and we have had over 21X) contacts Sin it was introduced in April 2023. A substantial proportlon of Ask Eve contacts are vla emall wlth the avera8e tlme spent on a spOnse tak11 20 mln5. The has been an increase In the number of calls wlth the average call 42 mins long which is over four times longer than the average GP appolntrnent. Thls level of engagement elves people the opportunlty to talk through their concerns. at their own pace. receive the individualised information and support tY need as well 35 ernpowerlng them to advocate for their ovm gynae health. Ifound your webslte so hew ondinfom• wtsh fdfound it just ofter dia9nosts. I so Impressed wlth the supwt Thrt Irecvedfroffl Helffj nurse speciolist. She was kind, corin supportlve ond rtened. I dth'tftelfvoltsh. lftltfvr thefirst tlme supported ond reossured. Helenfvllowed thmuqh with ollshe soid5he would. I wish more nurse 5perlaltsts were Ilke her. Her interortioffj nwnnff ondhstening skilts are wonderfrfjust what15 needed. I hove olreody shored your thurws infomiotion and Mllsupportyou in thefvture. The rnost common reasons for contacting Ask Eve a for infonnation about s18ns and symptoms, delay5 in treatment, concems aut ca. HPV, cefvi¢al xreenin& menopause and heredltary rfsks. Thls hl8hll8hts the valued and unlque rnle we have In cancer prnntlon and earty dia8nosis. Our outreath work contlnues to show an Increasi Nmber of contacts. frThn these emups. demonstrating the Impact of ¢)ur wor Our Ask Eve Nurse Service Cordinat0rWaS awarded a Polnts of Light Award in May 2023 and an MBE In DeCernr 2023 for tharltable seryices to women with gynaecologlcal cancer5. Information and Awareness Informatlon and Awareness is a cornerstone of charitable artivity at The Eve Aweal. In the relentle55 pursuit of athIng many people as posslble. wlth tiusted. ckar health Infornutlon, the team's effort5 have led to a series of impactful rnllestones thrOUgh¢t 2023. The Eve Appeal contlnued Its steadfast c(Knmitment to speak clearly and strongty, reach diverse communltle5 and empower individuals Wlth uucial knowledge about Eynaecological health and understanding the slgns and symptom5 of lynae cancer. Efforts In 2023 have provided a beacon of 20
Annual Report Incorporating a DirertO, Report and Accounts for the year ended 31 December 2023 best practice In the realm of 8ynaecolo8lcal health advocacy. wlnnlng awards ahnE the way. Below are some of thE hi8hli8hts of the Impactful endeavours of the team, showcaslng thelr unwaverlng commltment to empowering women. and reaching out in creatlve. unlque and Impactful way5. Across the whole year we had nearty 333,(X)O views of our website. and our gynae health information paEes had nearly 56.7110 vlews. (knr the course of 2023 our soclal wsts, which corrtaln vltal aynae health information and updates on The Eve Appeal, ached over 4.835.(KXJ people. We started work on the development of a new website, enBagin8 wlth hundreds ol our key audiences to hear about thelr needs. Despite the taboos around vmmen's health. The Eve Appeal were rnentioned In the media nearfv 590 times, where we shared 8ynae health Inforniatlon, detsils about our Ask Eve servlce. and commented on key storfes that were In the ne We wefe featured In outlets suth as iNew5. Huffpost, BBC online, The IndependenL The Daily Mail. The Sun, Mirror Onllne. BMJ. Mall Plus. The Tlmes, BBC Radio IWomen'5 Hour). The Guardian, The styIisL The Metro. Black Ballad, The Express. rrv New5. Podcasts: The Guilty Feminist. Media Stomi, Sknuld l Delete That? and Outspoken 8eauty. Crucially. the team were able to share research update5 and successe5 In the broadcast pres& wlth a number of stories appearing on natlonal televlslon and In the newspapers. January- CeThlcal Cancer Preventlon Week In January• fi>r Cervical Canr Preventlon Week ICCPW), we shared our'check Me OUY video across Instagram to encourage women and people wlth gynae organs to attend thelr cervlcal screening test when Invlted. Worklng wfth a creative agency on a prtrbono basls. thls unlque and ytrcatthinB vldeo reached over 185.oryj people wlth thls message. Marth- Ovarfan CancerAwareness Month Thls Ovarlan CancerAwarene55 Month {OCAM) we teamed up with doctors and nurses to develop vldeos With the key si8ns and Symptoms of ovarian carKer in Lfrfferent lan8uages- Bengall, Krlo. Gujarati. Fanti. Farsi and Yoruba. which was shared across ours and thelr thannel& Later in the year we promoted the videos on FabOok to w(xnen In the UK who speak those langua8es. the three vide05 were seen by nearty 165.500 people from these communltles. May- Get Uppy May 2023 saw our stxth year of the Get Llppy campal8n. We ran a YoyGov survey whlch found that only 7% of people had a good understarnllng of gynae symptoms before they experferKed them themself. We asked people what they wish they had known about wnae health when they were younger. to help people open up about their experiences and share the Important gynae health Infomiatlon we should all know. The carnpaign media and communications had an estimated total reach of 950 million, across our own channels Iwebsite and 50ciall we had a aCh of 1.3 mlllion people, We landed 34 plece5 of coverage. with an estimated wential reath of 950 mlllion. This tncluded several plece5 In The Sun, iNews and the Guilty Feminist potha5L 21
Annual Report incorporatln£ a Dlrectors. Report and Accounts for the year ended 31 December 2023 June- Cervlcal Screenlng Avareness Week For Cervlcal Screening Awareness Week thls year we shared tlps on how to make yDuf5elf feel more comfortable during a ceNlcal screening test, especially rfyou have any barrIe that make this partkularfy difficult. Our content through the week reached 45.5 people. 5eptember- Gynaecologleal Cancer AvAreness Month Durlng Gynaecological Cancer Awareness Month we shared key infwmation on hOm*eS and how they affert cancer rfsk through a woman's Ilfecycle. Our YouGov survey whlch found that only one in flve people know about the link between womb cancer and oestro8en and less than a third are aware of Its Ilnk wlth ovartan cancer. (er 900 people read our informative blogs on hormone5 and cancer rlsk and eaf menopause from cancer treatment over the Month. We gained 67 plece5 of covera8e in GCAM and our informative social media posts reached over nearly 102.000 people. We also ran a week-lon8 coElaborattve campaign. called Spot ChecK wftb G5K and Peathes Womb Cancer Trust to raise awareness of the slgns and svmptoms of womb cancer. The campalgn focus5ed In on abnormal va8lnal bleeding. We launthed a mlcrosite key infomiatlon and slgnposting, ran a campal8n on sla1 medla and had out of home adverts In seThlce statlon tollets acros5 the country. campal8n had an estimated potential reach of nearfy 135 mlllk>n people. With nearly 145,C4)O impressions across social media. 11 pieces of medla coverage and 3AOO people visiting the website. There were a total of 161 SterS in 24 seThice stations in the UK which an estimated 3 milllon people would have had the CnCe to see. Outreich- pikn project In 2013 we finished off our pik>t outreath project with south Aslan communitie5 in London. Birmin8ham and Manchester. We worked wlth four different grass roots organisation5 and charttles working with 50Uth Aslan women to c(roduce avrdreness resources and sesslons to ra5se awareness of the five gynae cancers. their key signs and symptoms and Information to help empower women to access medlcal supwt en they need IL We ran a totsl of 23 workshops wlth nearly 220 women across the three dtle& We asked the wmen what they felt they knew al)out the gynae health tOPiC5 both befo and after the sessions and average across 3 educational 5e55ions per BrP and 15 feedbad( questions. 68% of them sald they knew very Ilttle or a little before session, and afterwards M of them felt they knew Informatlon well or very well. 51nce our pllot proje¢ the number of south Asian w(wnen contactin8 Eve ha5 risen from just 1% of total callers to 8%. In 2023 we already reIVed flrther fundiTha fr(xn Gilead Sciences to continue our outreach wJrk and expand it to Black communities bn the three cities. and work is now Unde3V to Co-produce the content and sesslons wlth our working grwp of Black women and 8ra55 roots organisations. We are grateful to Gllead for thelr Eenerous suppor¢. with the impact dats PSertted above, we know that meanlnaful community engagement ha5 the potentkl to save lives. outrea You Need to Know In 2023 we ran a joint local campalgn with the North East London CarKer AllSance to r315e awareness of abnormal bleedln8 as the red fla8 symptorn of womb cancer in 81ack and %>uth Aslan women across the North East London bor(whs. We vmrked with the cancer alliance and a workSn8 8roup of 22
Annual Report incorporatlng a Director< Report and Accounts for the year ended 31 December 2023 women from the community to co•roduce campaign adverts and vldeos to get the ffssage out. Adverts were placed in community hubs. such as phamiacies and beauty salons. We ran 10 talks In local communlty centres and places of worshlp to over 225 peopk to share inforniat1 about abnormal bleedlng and womb carKer. The projert impact is being evaluated by an expert team at the Unlversfty of Lekester. Health hrfomiatlon In 2023 we gained our PIF rick accreditation - a symbol of trustworthy and ctrproduced health Informatlon whlch Is backed up by thorough processes for produclng health Informatlon to ensure It is accurate and aCssIble and Involves people who Et Is for from start to nnlth. We also launched a Guide to Lynth Syndrorne. for anyone k)okinE for inforniatlon on the inherited 8enetic r15k fartor for wornb. bowel and ovarian cancer- vknether someone has had a cancer dla8nosls, Is considerlng or Bolng through genetic testirva or has found out thry or a loved one has Lynch Syndrome. So far over 10(Xl people have downloaded aur gukle - whlch15 a150 awdllable In an Easy Read version - and over 4rxJo people have visited our webpage for infonnation. The Buide was a150 covered In iNew5. In 2023 we revamped our seneral 8ynae canr Information leaflets. We worked with a grnup of experts by experience to produce new, engagin& and accessible leaflets to raise awareness of the key sl8ns and symptoms of the gynae cancers In the general population. Slnce they re launched at the end of August our leaflets have been downloaded by over 1400 people. In 2023. 'Probabfy Nothin, The Eve Appears weekly online series hosted by Ask Eve's Ambassador. Karen Hobbs, continued for its sixth and seventh serie4 with eight new 454ninute conversations wlth expert5 broadcast Ilve on our 50clal medla channe15 totallSn8 In over 10,CW vlews. Throu&h serles seven we dlscussed topks related to 8ynae canlS and menopause, Indudlng what cancer symptoms to spot if you are post-mewusal. early Menopause due to cancer treatmenl and fertlllty optlons for women and people vAth ynae cance The Ask Eve team dellvered several workplace lunch and learn se55k5 th55 year. Th15 proyarnrne. whith takes Eynaecological health into the workplace and on to the corporate Wellbei agenda, has been developed into an employee programme. The Every Woman Promise. The Every Woman Promise sees employers make a commitment to wornen's health in the workplace and has been Incredlbly well received by empknyers and empknyees alike. Fundraislng Frnm the Gener Publlc We are overwhelmed by the contlnued 5UPPOrt of all those who thoose to donate and fundraise toward5 our work during year and the difference they are makinz. Whether taking on virtual challeftg running marathons or donatlng in response to our appeals, generou5 people acr055 the UK wntynued to pull together and do what they could to help make Bynaecologlcal carKers dFSeases of the pasL G5ft5 from the general public account for the majorlty of our Incorne and so It Is only thanks to these In5pirin8 and 8enerous Ind5vlduals that we can deliver fund WOfld<lass research, our cancer Information service Ask Eve and our v5tal awareness ralslna wor We are a150 touched by the Incredlble supporters who chose to include a gift to The Eve Appeal in 23
Annual Report incorporating a Director¢ Report and Accounts for the year ended 31 December 2023 their Will. These Bifts make a real and lastlng difference that wlll benefft all those affected by gynaecologlcal ancers for generations to corne. IV5 an Incredible legacy to leave. From Buslnesses We are truly thankful for the on8oin8 5UPPOrt of our lonB-terni corporate partners. Indudln8 Tesco, Cosmetic Executive Women UK (CEW) and Saks Hair and Beauty Salons, who continue to support The Eve Appeal in so many way5. We are also incredibly 8rateful to all of those businesses that joined our wellbeina pro8ramme lthe Every Woman Promise) requested lunth and learns or sUPrted u5 in other ways throughout the year. We would specifically Hke to thank the League Managerfs Assoclatlon for thelr phenomenal ongoin8 supporL We again ran our Il38shlp Get Lippy campaign in Mayo a campaign which sets out to encourage everyone to speak up about gynae cancers. We were dellghted wlth how many Incredlble brand5 chose to partidpate In donating IA of sales from speclfk products In the month to The Eve Appeal. This was again. our most successful campal8n to date and we truly apyeciate eath and every bRnd that partlclpated and every member of the public who purthased these products and contflbuted to Its succes& A speclal thanks. also. to our Get Uppy lead partner Tesco who have supported the campaign snce its Inceptlon. From Trusts. F(Mndations and Statutwy Fun&1 We are hugely Brateful to have benefitted from the support of numerous Trusts and Foundations throughout the year. Thanks to their support we could lund vital research into rarer gynaecok)8ical cancer5, malntaln our Cancer Infonnatlon Serv1 Ask Eve and dellver outreach se5slons wlthln tarzeted communltle We are atso delithted to have received the second instalment of our grant from the Department of Health and Soclal Care (OHSCI. Thls fundln8 Is enablln8 W to dellver our Every Woman Promlse programme to Small and Medlum slzed Enterprtses- ensurln8 more buslnesses are able to SUPPOrt woiiien's health in the workplace. Impact Despite the many challenges of capturlng the Impart as a small medlcal research and advocacy charity, we continue to support real change- In transf0rn7atlve research dlscovery• In cllnlcal practi. in accessing appropriate care, in developlng a broader understanding about gynaecological health, In reaching women who are not sUprted. and in breaki down the barriers that vmmen face In managlng their health. Impact can be difficult to judge through numbers alone: SUc$S can mean a single call encouraging someone to attend a ceryical screenin8 appointment or feasibility fundin8 to a small-scale researth project. Our relatlvely small research Investments have enabled our researthers to levera8e SiBnificant follow-on funds fr(xn natlonal and intemational funding bodles. New awards made In the past 12 months provlde the fourKlations of novel researth that could make quicker diagn05i5 and ultimately Improve treatment outcome5. It 15 Particularly yatifyiwd for all of our Stakeholders to See that riskier 24
Annual Report incorporatln£ a Director5. Report and Accounts for the year ended 31 December 2023 research, 5UPPOrted In the early days, has many years later led to 1rnFrtaftt changes In dlnlcal practlce. Staff, trustees and volunteers have contlnued to shLlW incredible commitment to the mission of The Eve Appeal. Our progress in this rni5s1on - a futsire where fewer women are dlagnosed wlth. and many more women sur¥ive. 8ynaecolo8ical cancers- has been unyieldin& and the impact of these investments spurs our community on furt. Research Impact Overvlew Despite fundin8 earty-rt4e. 'riskierf and novel projects. The Eve Appeal has an extraordlnary track record of success when it comes to research impacL Below are a few examples of the Thpart of legary projects, as well as current funded projects. The Eve Appeal funded PROMISE study, whlch started In 2011, continues to ceIve slgnltlcant follow-on fundln8 from a ran8e of organ15ations Induding the Medlcal Research CourKil, Cancer Research UK, and the NHS Innovatlon Accelerator Fellowship scheme. They aim to develop and valldate models for risk stratfflcat5on. earfy detectlon and diagn05i5 of ovarlan cancer which incorporate dlnlcal. epldemkAo8lcal. geneti4 woteomic arKI Imaglng dats and to then assess how best to apply them In large populations. The goal 15 to transform outCon5 for people at risk from ovarlan cancer. giving them a far 5tron8er than of survlval. The bloresource created durin8 the course of UKcrO re•branded as the UKCTOCS LonBitudinal Women's Cohort {UKLWQ. contlnues to supp¢)rt academic and Industry collaboratii>n5. UKLWC ha5 Its own dedlGited access and 8ovemance Strlure to support wlde and efficient sharin8 of samples and dats. The resource therefore provides an ideal settAng for case control studie5 for early detection biomarker5. Longitudinal samples a150 provide a unique opportunity to improve biomaTker performance for sCreenid through development of longitudinal algorithms. The UKLWC bioresource has to4ate sUPPOrted over 70 collaborative projects, wlth over 65 publications resulting from these collaboratlons to dats. The research led by Professor Sadaf Ghaem-magharnl from Imperlal Colle8e London has developed a tool to Instantly diagnose ty rule oirt womb cancer. If used in cniC. the Intelll8ent knlfe (IKnlfe) technolo8y- and the hi8h dta8nostlc accuracy and posltive predictive value- could provide a dia8nos15 Within mlnutes for people with abnornial vaginal bleedlng. Thls would speed up access to treatment for those w5th womb cancer. as well as reducin8 the stress and anxiety of waltlng for results. The next step will be to run a muttkentre trlal. to enable the tethnOlo ta be put Into cllnlcal practice. We contlnue to support the Professor Wldschwendterfs Unfver51ty ColleEe Londorfs strateBIc programme thmu8h the funding of the UCLH lab te3nK In 2022. nine new academlc papers relati to the results of Eve Appeal funded projects were pubtished in journals Includlng Nature Communlcations. Journal of Cltnical Oncology. Gerrtxne 81ology, GerN>me Medlcine. Uinical Epigenetlcs and the International loumal of Cancer. Further research was pubfished in 2023. and with the support af The Eve Appeal. the team continue to drlve the translation of this research Into clinically actionable tests. Eve's support of Professor Willlam foulkes at MCGIII Unlverslty (Montreal, Canada) was Instrumentsl in helping to establish a research realstry that would facllltate access to research data and matsrials for the study of small cell o¥arlan cancer (SCCOHn. The fvndlng contlnues to support Q&A sessions wlth the publlc on SCCOHT and the re8iStry has had an increase in requests for advice from patlents 25
Annual Report Incorporatlng a Directors. Report and Accounts for the year ended 31 December 2023 and famllles. partlcularfy around Ilf&changing de55 like whether to perform preventlve oophorectomles (the femoval of both ovarles). Our lon85tandlng relatlonshlp w6th Professor Ranjlt Manchanda at Queen Mary University in London h35 focused on heredltary rlsk and populatlon testlng of 8RCA mut3tlon5. Thls work has led to the start in sprfng of 2023 of NHS population testi for BRCA undertaken through the NHS Cancer Screenlng Prograrnme. We have de¥ek) connections with Jewish communlty organlsatlons. to support stakeholder engagement and support structures and netsvorks. and wlll support outreach. awareness and en8a8ement pro8ramrne5 8olng forward. Vulval cancer remaln5 a slBnfficantly Under-researdd dlsease. Wfth over 1.4(¥J cases diagnosed each year in the UK and an estimated 45AKKI globav there is potential for sdertlfic advarKes In thls area. We are pleased to be supporting two earCh initiatives in this area. Data the first sthdy led by Dr Jackle McDerniott examlning blomarkers for the earfy detection of vulvar cancer and pre- cancer by spatlally re501ved gene expression will be presented at a global open meeting in 2023 to share de¥elopments and next steps wrth this communlty. Working with the National Cancer Research Institute, we hope to develop a network to support those who are advancln8 knowledge around vulval cancer. By wovl&in8 5uppofL sharln8 knowledge and offerfn8 OPPOrtunltles thls WMI enable re5earcher5 to dlrert thelr effort5 towards the most promi51rq hypothese& A second project on vulval cancer, led by Professor Maria Kyr8iou at Imperial Colle8e Landm, Is focused on early dia8nosis of precancerous and cancerous lesions. Dia8nosis of the dSsease ts dlfficuft. and surgically treatin8 the thsease is challen8in8. With the support of our generous dDnors to the Rare Gynae Cancer Fund, Maria and her team are developing novel technolo8ies- called laser-3s51sted Rapid Evaporative lon15ation Ma55 Spectrometry ILa5er-REIMS) - whkh could enhance dla8n0515 and Intr3-oper•tive decislon makln& and this could lead to slgnificant benefits and reduced morbldlty forthls commoth elderty populatlon. Thls would rnlnlrnise the need for repeat Visits. unnece55ary extensive sur8ical removal of skin whi15t optlm15in8 clear4nce and mlnhnlse repeat surglcal procedure by enhanang margln clearance and IntraoPerati¥e senne1 lymph node dla8nos15. The proposed technology has the potential to offer a single, rdpld, low<ost and objective test for the early detection and further develop into a tool for bedside dia8nosis. We will update our supporters a5 the Study progresses. and the team have already won prizes and recognition for their work . The second Rare Gynae Fund woject led by Professor Sudha Sundar has recelved matthed and follow-on fvndlns In its first year and contlnues to seek addltlonal sUPPOrt for thelr work They recruited an excellert team to progress their work In understandin8 mucinous ovarian canw. The team have been bulldlng coHaborations both nationally and internationally and have had signifKant patlent engagement through focused 8roups and on Social media. The team are also maklng efforts to reach out to ethnlcalty diverse communities and hove translated their work into multiple languazes. The team have a real opportunity to derive new In5iihts into this Ifisease to help women wlth mucinous (warian can¢ff. Information and Awareness Impact En8a8ement across the range of actlvhies connerted wlth our many Informatkjn and awaren$ Inltlatlves Is an excellent indlcator of impart. With hundreds cf thousands of vlevts to our website and mllllons of vlew5 across social metha channels. The Eve Appeal has become the 'go-to' source for I Ckn¢ef Aeseath UK 26
Annual Report incorporatlng a Directors. Report and Accounts for the year ended 31 December 2023 honest. trusted health Informatlon and support. From stories in the rnainstream press downloads of focused health informatlon resources Ilke our Lynch Syndforne Guide, large•scale campal8ns across the calendar year and partnershlps with a range of stakeholders to ctrproduce Inrrt>vatlve ways of engagin8 With those who are experiencing social and health Inequalltie8 we know that this tsr8eted work has the potential to save Ilves. We are grateful for the support of orlanisations that help us to do more and reath more people. Whlle we know we are making a difference. fvndlng for outreach Is limited. We have Identlfied communltles In need and will continue our effort5 to reach (xit to as mary as p055ible. Ask Eve Nurse Service Impact Ask Eve has provlded a lifellne for so many vmmen unable to access 8ynaecolo8ical care to address thelr concerns. It ha5 helFRd many with a new 8ynaecolo8ical cancer diagnosis to understand thelr sltuatlon. and access support. It has provided a 5UPPOrtive and empathetic ear to those fadn8 extraordinary challenges. The many quotes and te5tlmonlals from fallers attest to thls: "Manythanls to the MmderfulEveAppealstaff. knpartKular Tracle. for5UPPOrtln8me through an exceptionaltyisotstingsituation due to a veryrdre dlagnosls. ltwld be In a verybad %MTlhoutyourhelp. Iwantto use mylrndous expeiiencesandconstantgaslloptlngand thsmlsslngolserlous SPrnS to tyand enactsome changes. Ifsjustunacceptabie s%at some bwmenhave togo thmW to rncer* Supportfvle prnblems. Thanks forall>Yiu do.. Our extraordlnary team of gynae nurses are stretched to the Ibmlt and it would be Ideal to grow the team to support more people. The challen8e in 2024 wil be to continue demonstratlng Impact to Erow our semce for more wom. We are grateful to everyone vtho supports Ask Eve and contributes to its on8oln8 development and success. The added value of Ask Eve Is summed up by one of our users: -you ore all amazlng ond we are so lucky to o charity lthe youl" Fundralslng Impart Our incredible supporters donated £1310542 tOVArds our WO durfn8 the financlal year. We are overwhelmed by this oryoln8 generoslty, and we are truty thankful to everyone for thelr donations and support. They have lPed to fvnd our cancer infomation seNlce. Ask Eve. vftal research vla our Rare Gynae Fund and 5UPPOrted our wider work tu help rnake 8ynaecological cancers dlseases of the past. Some standout achlevements Indude: Contlnuln8 our partnetship wlth the Department of Health and Social Care IDHSCI to brlng Bynae health inf0mtIon to small buslnesses: Another record-breaking year for our annual Get Llppy campai8n-workln8 wlth auty brands to donate IO% of sales on specific products during May: 5ecurin8 a partnership with The Blg Glve rneanin8 all donatlons to Ask Eve, our nurse4ed ancer information service. were doubled duri the campaign perlod. 27
Annual Report incorporating a Dirertor< Report and Accounts for the year ended 31 December 2023 Structure, Governance and Management Organlsatlonal structure and declslon maklng The Charftyls 8oveff*d by a Board of Trustees who a members and also dlrectors of the Charity for the purposes of the Companies ACL The Board Sets the strnts8lc dlrettlon of the Charity ensurfng that the charitable purposes of the Charity arE met. Day-tTrday runni of the Charity is delegated by the 8oard to the Chief EXeart1 Officer. The Eve Appeal constder5 each of the Trustees to be independent in character and Judgement and understands that they have na relat5on5hips that are Ilkely to affecL ar could appear to affect, their judgements with regard to the Charity. Dedarations of interest are requlred from new Trustee5 upon appointment and every meetir¢ of the 8oard requi$ that any new interests are declared. No remuneratkn 15 provided except for reasonable travel and subsSstence costs; in 2023 thls fl8ure was EO. There are two Committees vthich fflake recommendations to the Board: the F5nance & Audlt Commlttee and the Research Cofflmittee. The purpose of the Flnance & Audlt Commlttee Is to en9Jre that a strate8lc approach Is taken in the areas of finance. rlsl audtt, remuneratlon and other operatklnal areas. The Finance & Audit Committee is comprised of at least four members, all of whom are Trustees. who give detailed conslderatlon, on behalf of the Board. to these matters. The Research Committee proviths scientific research advice and works on the CoMMendatIonS of the external Research Advisory Committee for newfun(fing decisions. These recommendations are viewed In light of the charirf5 mlsston. charltable oblectives and finandal position. and the committee makes recommendations and provmles advice to the Board of Twstees. The Charlty had one 100% owned sub51dlary company In the year. Eve Appeal Limited is a trading company that dlstributes its profits under Gift Aid to the tharity. In Z021, In recognltlDn of the Charws 9JPPOrt for key support prngramffles, the Principal Inve5ti8ator. Profe55or Martin Wid5chwendter ha5 Eifted The Eve Appeal 5hare5 in a company. Sola DiaBll05tics GMBH which will takinB forward innovative diagnostic tests which are at an earty st38e of development. Any profits arising from the venture will be fed back into academic nd1(al research pro8ramrne& In 2023 Sola Dia8n05tlcs GMBH had yet to make a profit. Trustee appolntment. Inductlon and tralnlng Trustees are appointed in acconlance with the Memorandum and Articles of Assoclatlon, takln8 Into account the benefrts of appointlng 3 PerX who 15 able. by virtue of his or her personal or professional qualifications and experien. to make a contriknrtion to the pursuit of the objects or thE management of the Charity. Tru5tee5 and staff consider the 5ki115 Bap5 formed by departin8 Trustee5 and both OnIV advert15e 28
Annual Report incorporating a Dirertorf Report and Accounts for the year ended 31 December 2023 for and nominate appropriate individua15 With skn11s to match beforn recommendation to Board for ppolntment. References are taken before appointment 15 formalised and prospective Trustees are then proposed and appointed at the AGM. The Charfty undertakes a comprehen&ve induction prograffffie for all new Trustees, which includes Indurtlon materlals relatln8 to its purposes and finances, the powers and dutles of the Trustees and infomiation about day-to-day runnlng of The Eve Appeal. Xey documents are provkled, such as the Memorandum and Articles of AssocSat1o the Charity Comm15slon'5 Essentlal Trustee gulde. up-t date accounts, and minutes of the n*)st recent Trustee meetings. Prospective Trustees rnay also attend relevant Trustee meetln8s as an observer as part of the inductlon process alongside introdurtlons to key people and places. Trustees cont5nue to be sUPPOrted through ongotn8 tralnln& with skills quIremertts regularly reviewed. The Trustees who served In the perbd under review were: Melanle Rlchards CBE (Chalr of Triistees) (Reslgned. 071021241 (Reslgned 1711112013) Ichalr. Hnance & Audlt Cornrnittee) (Appointed OV07n020} (Appointed 04/iin0191 (Appointed 29109n0161 (Appointed 26110120201 (Appolnted 29105120121 Jenny Leonard Tamara Box Sarnh Clark lan Dr Chrlstlne Ekechl Dr lan Jacobs ir Sidonie Kin8smill Sarah Morrls (Reslgned 2yOln4) (Appointed 19112n0191 (Appolnted 27110120211 (Appolnted 04111110191 (Reslgned 20102m1231 (Appointed 26iion0201 (Appolnted 18/ion0231 (Appointed 1811012023) {Appointed 1811012023) Marion (YHara Cathy Pitthamvwiky Kathleen Prltthard Dr Adam Rosenthal Sally Bailey Dee Brecker Emma Dean Declaration of Interests All Tru5tee5 and staff are required to declare their interests. and any payments (includinB. but not limited to, beneffts in kind such as Bifts, h05Pitality 5hoppinrJtravel concession5. preferential treatment, etcl received in connection with their role in The Eve Appeal where Such intere5t5 would. or might. conflirt with, or otherwise influen their decisioTrmaking in respect ol the Charity's activities. 29
Annual Report Incorporatln8 a Dirertor< Report and Accounts for the year ended 31 December 2023 Staff A Sensor Management Team comprisin8 the Chief Executlve. the Fundralslng Dlrector, the Head of Finance and Head of Pro8rammes allows for diStntIon of organisational responsibllity and both staff and Trustees continue to be happy wlth the Structure. The CEO has partlcular responslbllity for 155ue5 latiftg to governance and for the financlal management of the organlsatlon. The Eve Appeal has 21 pemianent members of staff and the Trustees record their appreciatlon of the efforts of the staff. who have again made an enomious contributlon to the success of The Eve Appeal and its mission during the year.
Annual Report incorporating a Dirertorf Report and Accounts for
the year ended 31 December 2023
Volunteers and Advorates
Volunteers forrn a vitsl part of The Eve Appears operat10. from our dedicated fvndrat5er5 holdln
bake sales or sportln8 events. to those who help staff at larger events Ilke Festlval of Carols or al$t
wlth day-t
Annual Report Incorporatlng a Dlrectors. Report and Accounts for the year ended 31 December 2023 Safeguarding Pollcy Our safeguarding poliLy ha5 been reviewed arnl updated durfr¥ 2023 and all staff and Trustees offered tralnin& We have a 5afeBuardln8 lead Trustee and a dear escalation process In place. Safeguard7nz155ue5 and concern5 are notif to the Board as part of the quarterly reporting process. The Eve Appeal believe5 everyone ha5 the ryht to live free from abuse or neglect regardless of a8e. ability or disability. se4 race. reli8ion. ethnic 0ri8ln. sexual orientatlon. marStal or gender sLItUS. The Eve Appeal15 commltted to creatinE and mairrtalninB a safe and positNe environment and an open. listenln8 culture where people feel able to share COnm$ wlthout fear of retribution. The Eve Appeal acknowledges that safeguarfin8 is everybodfs responslbillty and Is cammltted to prevent abuse and neBlect thrnugh safeguardlnB the welfare of all adults involved. The Eve Appeal recognlses that health. welkbeing, abilty. disability and need for care and support can affect a person's reslllerKe. We reco£n5se that some people exFertence barrlers. for example. to communication in raising concerns or seekln8 help. We reco8nlse that these factors can vary at dlfferent points in peop1¥5 live& Safe8uardin8 artions tsken by The Eve Appeal will be consistent with the prlndples ol aduft safeguarding ensurin8 that any actlon taken Is wompL proportlonate and that it includes and respects the volce of the aduft concerned. 32
Annual Report incorporating a Dlrectors. Report and Accounts for the year ended 31 December 2023 Flnanclal Revlew 2023 Trnnsactions and financial Posltlon At December 2023 year end. we reported a surplus of £362,326 in unrestrirted reserves to carry for¥vard into 2024. This surplus comprlses fvnds of £182.326 above Our aareed operatin8 reserves level of £180,CMJO. In 2023 we Introduced a Research Fellowshlps Pro8ramme. supportlng our legacy programrne with Prof. Martln Wldschwefidter. as well as holdinz a researth open call. We have an ambitious programme for 2024 grant award5. Ending 2023 with substantial unrestricted reserves places The Eve Appeal a posltlon to meet ow award ambitions. In summary, we begin 2024 in a cautious but stable posltlon wlth £362,326 in free reseThes and an overall $h balance of £928.895. Fundin8 FundraiJln8 pollcy Se¢tlon 162a of the Charltles Art 2011 requires charities to make a statement re8ardln8 tundralslng actlvltle& legislation define5 fvndra151n8 as 'solicitln8 or otherwise procuring money or other property for charitable purp05e<. Suth arnounts receivable are presented In our accounts as 'donatlons and voluntary Incom¥. We conflmi that all sollcltatlons are manaied internalEy, without invofvenrt of commercial partlclpators or professional fundraisers or third partles. The day-to4ay management of all Income generation Is delegated to the executlve team, whlch 55 accountable to the Trustees. We have received no complalnts In relatkn to fvndfalslng activitle& The Eve Appeal Is funded wincipally by voluntary donatlon5 from Indlviduals and community groups who continue to 5UPPOrt our work and mlsslon. Corporate sponsorship and donations also account for 3 518nlflcant proportlon of our funding. Wlthout this support we would not be able to operate. and we are Incredlbly Bratelul for every penry that is donated. Risk Management The Trustee5 have assessed the rnaior risks to whith The Eve Appeal15 exposed and are satisfied that Systems are established to mitizate the Charitys exposure to those rlsks. These risks are detailed on the Rlsk Re8lster for The Eve Appeal, trrforThMtion on the current practlce and strategy used to mltl8ate the rf5k. The Re8lster Is revlewed quarterly by Trurtees. The current R5sk Re8lster pays partkular attention to the rf5ks around the Impact of the pandemic and the on*oln8 economic crises on inc(w and operatlons. researth not rexhing intended objectives. fundralsing targets being rni55ed. kn55 of key individua15. rr failure fincluding cyber security risk) and incorrert inforniation being provided on a health issue. The inte8rity of medical inforniation provided by the Charity is managed by a8reed peer-revlewed protocols, with infornHtlon standards appfied xr055 all materials and chamets. A balanced portfolio of lundralsin8 actith spreads risk to reduce any potentlal lrnpact. Regulaf 33
Annual Report incorporatong a Dlrectors. Report and Accounts for the year ended 31 December 2023 financial plannin& indudin8 re4orecast of fvndralslng Incorne and expendlture, ensu5 early interventions can be made. Reserves Pollcy The 2023 annual revlew of the reserves policy deterniined that no adjustment was required to the figure as set In Z022 of £180,LfrfJ. Thi5 fi8ure is set by the Board as a tarEet of holding £180.IXIO in free reseThes. Thls target is based on the (tIn8encY for wind up funds. calculated to satisfy all the Charity'5 liabilitie5 in the event of d05ure. In real term5. £180.(MXI represents just under three month5. bu(eted ewjenrfrture. eXdU1ns expenditure on researth yants. The Board will continue to review the reserves polKy annually to ensure It remalns apwopriate to the needs of the Charity in the context of the economic cllmate. Going Concern The Tru5tee5 have reviewed the CharW5 flnanclal posltlon. taklng Into account the leve15 of re5erve5. cash. committed income included in the accoun future plans and its 5yStem5 of financlal and risk rnana8ement. Trustees believe that the Charity is well placed to manage operational and financial risks successfvlly. AcCOrdilY. the Trustees have a reasonable expectson that the Charity has adequate resource5 to continue Sn operatlon for the foreseeable future and con51der that there are no materlal uncertalntles about the yourfs ability to continue as a £oln8 concern. Grant MaklnE Pollcy The pollcy of the Trustees ts to fund w)rld<lass ffledkal researth that will make the biggest Impact In savlng women's Ilves from 8ynaecolo8ical cancer5. includin8 fun% pro01flnClPle WO to enable the award of future fundlng. As a member of the Association of Medical Research Ch3rfties, we have developed a strategy and fvndln8 dectslon-maklng proce$5es that meet strict awardlng criteria and review. and recommendatloTrs are made by Independent experts in the research fleld. Statement of Trustees. Responsibilities Trustees (who afe akn directors of GynaecoloBy Canor Research Fund for tr purposes of company law) are reSpOlbIe for preparlnc the Trustee5' Report and the financial statements in accordance with appllcable law and Unlted KIngd Accountlng Stsndards Iunited Kin8dom GeneraHy Accepted Accountlng Practice). Company and charity law require5 the Trustee5 to prepare financial Statements for eath financial year. Under company law the Tru5tee5 must not approve the financial statements unle55 they are 5ati5fied that they give a true and fair view of the state of affairs of the charitsble company and the roup and of the incomin8 resource5 and application of reSoUe$, induding the income and expenditure. of the charrtabk £mup for that period. In preparing these financial staternents, the TTUStees are required to:
Annual Report Incorporating a Dlrector< Report and Accounts for the year ended 31 December 2023 Select suftable accountln8 pofiues and aY them consistently. Observe the rnethods and prlnciples in the Chaiities SORP (FRS 102); Make jud8ernents and estimates that are reasonable and prudent: stste whether applicable UK Accountln8 Standards have beeft followed, subject to anv materlal departufes disclosed and explained in the flnancl31 ststements: Prepare the financlal sL7temerrts on the Sol concern basis unless it is inapwopriate to presume that the charitable company wlll contlnue In buslness. The Trustee5 are responsible for keeping adequate and proper accountln8 records that are 5uffic5ent to show and explain the charltable compan$ transactions and disclose with reasonable accuracy at any tlme the financial posltlon of the tharftable company and enable them to ensure that the Ilnanclal statements comply with the Companles Art 2006. the Charltles and Trustee Investment (Scotland) Act 2005 and the Charltle5 Accounts (Scotland) Regulatlon5 2006 la5 amended). They are also re5ponsiblp for 5afeguardlng the assets of the charltable company and the group and hence for taking reasonable step5 for the prevention and detectlon of fraud and other Irregularltles. In so far as the Tru5teE5 are aware: The Is no relevant audit inforn4tlon of whlch the charltable companvs auditor is unaware; The Trustees have taken all steps that they ought to Ive taken to make themselves aware of any relevant audit infomiation and to estab115h that the audltor 15 awa of that Infomiation. The Trustees are responslble for the malntenance and integrity of the corporate and financlal information included on the charftable comparfs website. Le8islatlon in the United Kingdom governlnE the preparation and dissemination of financial statements may differ from le8islatlon In other jurisdictions. This report has been prepared In accordance with the speclal provlslon5 relatln8 to small companies within Part 15 of the Companies Art 2(X)6. Onbe of the board: Tamara Chalr Date: i# May 2024 35
Independent Auditors Report to the Trustees of Gynaecology Cancer Research Fund Opirdon We have audSted the flnanclal statements of GeCOlOgY Cancer Research Fund (the 'parent charitable companv) and Its subsldlartes (the 'grourf) for the year ended 31 December 2023 whlch comwise the Group Ststement of Financial Activitie5 (indudin8 the Group Summary Income and Expenditure Account), the Group and Parent Charitsble Company Balance Sheets. the Group Cash Flow Statement and notes to the financlal statements. Includln8 a summary of 518nificant accounting pollcles. The finandal portIng framework that ha5 been applied In thelr prepardtlon is applicable law and Unlted Kingdom Accountlng Standards. Includln8 Flnandal ReportSng Standard 102 The Flnanclal Reportln8 Standard appllcable In the UK and Repub15c of Ireland (United Kingdom Generally Accepted Accountin8 Practice). In our oplnlon the finandal statement glve a true and falrvlew of the state of the gmup's and the parent charltable companvs affairs as at 31 DecemtrRr 2023 and of the group's incoming resource5 and appllcatlon of resources. indudln8 Its Income and expenditure. for the period then ended: have been property pPared In accordan wlth Untted Klnadom Generally Accepted Accounting Practi. and have been prepared fft accordance with the Companies Act 2006. the Charltles and Trustee Investment (ScotlaNI) Act 21XIS (as amended), regulations G and 8 of the Charltle5 Accounts (Scotlandl Regulatlons 20C (as amended) and the CharAtles Act 2011. Basis for opinSon We conducted our audlt In accordarKe wlth Internatlonal Standards on Audltlng (UK)11SAs (UK)) and appllcable law. Our responslbllltles under those standards are further descrlbed In the Auditorfs Responsibilities for the audit ol the financial ststements section of our rem. We a independent of the charltable company In accordance wlth the ethlcal requlrements that are relevant to our audit of thE finanaal statements In thE UK incIlinE the FRCS Ethical Standard. and we have fvlfilled our other ethÈcal responsibilities in accordance vth these requirements. We believe that the audlt evklence we have obtalnedls sufficlent and approwkte to provlde a basls far our oplnlon. Concktslons relatlr4 to concem In audltlng the fSnanclal statements. we have conduded that the Triistees. use of the 8oin8 concern basls of accountln8 In the weparatlon of financial slateftnts Is appropriate. Based on the work we have rfoned. we have not identified any material uncertaintles relating to events or condltlons that indrvidually or collectivety. may cast slgnSficant doubt on the charitable company's ablllty to contlnue as a 8oln8 concem for a period of at least twelve months from when the financlal 5tstements are authori5ed for issue. Our re5ponslbllltle5 3fKI the responsibilities of the Trustees with respect to golnB concern are described in the relevant sectM>ns of thls reporL Other information The other Information comwtses the Information induded in the annual report. other than the financial statements and our auditorfs report thereon. The Tru5tee5 are re5ponsibte for the other
Independent Auditors Report to the Trustees of Gynaecology Cancer Research Fund Inforniatlon. Our oplnlon on the finanaal sL*ernents does not cover the other Inforniatlon and, except to the extent otherwise explicitly stated In our report. we do not express any farm of assurance conclusion thereon. In connection wlth our audlt Of the financial statements. our responsibility is to read the other information and. in doing 50. consider whether the other Inforniatlon Is materialty inconslstent wlth the flnanclal statements or our knowledge obtalned In the audit or otherwlse appears to be materlally mlsstated. If we identify such material inconsistencies or apparent rnaterial mlsstatements, we are required to determlne whether there is a material misststement in the flnanclal statements or a material mi5Statement of the other infornutlon. If. based on the work we have performed. we condude that there Is a material ffllsstatement of thls other infomiatlon. we are required to report that facL We have nothlng to POrt in thls regard. Oplnlons on other rnattor5 prexribed by the Cornpams Act 2006 In our opinion. based on the work undertaken in the ctyjrse of the audlt the informatlon given In the Trustee annual report for the financi31 period for which the financial statements are prepared is consistent with the financial statements; and the Trustee¥ annual rewt have been prepared tn accordance wlth applicable lepl Tequlrement5. Matters on whl¢h we are requlred ts report by exceptlon In the Ilght of the knowledEe and understanding of the group and parent charitable company and It5 envlronment obtsined in the course of the audit. we have not identified materfal mi55tatements in the Trusteeg annual report. We have nothing to report In respect of the following matters where the Companies Art 2006. the Charitie5 Accounts Iscotland) Regulatlons 2(MJ6 (as amended) and the Charities Act 2011 require us to report to you if. in our opinion: the parent charitable company has not kept adequate and sufficient accountlng records. or returns adequate for our aKlit have not been received from branthes not v551ted by us. or the parent charltable comparfs finala1 statements are rt in 3reernent with the 3ccouritinB records and returns: or certain dlsclosures of Trustees. remuneration spec6fRd by law are not made; (Y we have not received all the Infomiatlon and explanations we requlre for Dur autht," or the Trustees were not entitled to prepare the financial statements in accordance wlth the small cornpanies regime and take advantage of the small companies exernption In preparin8 the Trustee< Annual Report and fnmn preparln£ a rtrategic report. Responslbllltles of Trustees A5 explatned morE fvlly in the Trusted reOnsIbIlIt statement set out on page 34, the Trustees {who are also the dirertors of the charitable company for the purposes of company law) are responsible for the preparatlon of the finènctal statements and for being satisfied that they 37
Independent AlitorS Rert to the Trustees of Gynaecology Cancer Research Fund give a true and falr vlew, and for suth Intemal control as the Trustees determlne is necessary to enable the preparation of financial ststements that are free from material misstatemenL whether due to fraud or error. In preparing the financ5al 5tatsments. the Trust&s are responslble for asses51n8 the 8roup and parent charitable compan5 ablllty to continue as a goln£ concem, disd05in& a5 applicable, matters related to golng concem and ustng goin8 concwn basls of accountinB unless the Trustees either intend to liquldate the group or parent charitable company or to cease operatk>n5, or have no rea115tlc alternative but to do so. Audltorfs rnsponslbllltlo% for the audlt of the financial stataiients We have been appointed as aulfitor under Sectknn 44111{¢} of the Charftles and Trustee Investment (Scotland) Act 21x15, the Companie5 Act 21x16 and Section 151 of the Chatities Act 2011 and report to vou Sn accordance with regulations made under those Acr% Our objertiVES are to d>tain rea)nable assuran about whether the financ5al statements as whole are free from material mS5Statsment. whether due to fraud or error. and to Issue an auditorf5 report that includes our oplnlon. Reasonable assurance Is a hl8h level of assurance. birt Is not guarantee that an audlt condutted in accordance wlth ISA5 (UK) will always detect a mater ial mlsststement when it exists. Mlsststements can arise from fraud or error and are cmsidered materfal if, individually or In aure8ate. they could reay)nably be expected to Influen the economlc dK151ons of Use taken M the basls of these financial statemen A5 part of an audlt In accordance wlth ISAS (UK) we exercise professional jud8ement and malntain professional sceok15m thrwhout the autht. We a150: Identlfy and awss the risks of materlal mlsstatement of the financial statements, whether due to fraud or error. design and perfofm audit procedures re5pon51Ve to those risk5. and obtaln audit eVIden that Is sufflclent and appropriate to provide a basis for our opinion. The risk of not detertlnE a material mi55tatement resulting from fraud Is hlKher than for one re5ultlnE from err¢x, a5 fraud may involve collusion. for8ery. Intentional omissions. mi5repre5entattons. or the override of Internal control. Obtaln an undetstanrfing of Internal control relevant to the audit in order to de5 audlt procedure5 that are appropriate in the circumstances but not for the purposes of expressing an oplnlon on the effectiveness of the 8roup and parent charitable companvs Intemal control. Evaluate the appropriatene55 of accountlng policies used and the reasonableness of accounting estimates and related disckn5ure5 Made by the Trustee Conclude on the approprlateness of the Trustee< use of the golng concern ba515 of accountlng and, based on the audit evldence obtslned. whether a material uncertainty exists lated tt) events or condltions that may cast siznificant doubt on the Broup and parent compan5 ability to continue as a golng concern. If we conclude that a rnaterial uncertalnty exists. we are required to draw attention In our audltorfs report to the related dIsclosu3 In the financiaf statements or. rf suth disdosures are inadequate, to Modify our opinion. Our conclusions are based the audit evidence obtaineil up to the date of Lwr auditorfs report.
Independent Auditors Report to the Trustees of Gynaecology Cancer Research Fund However, future events or condftlon5 may cause the group or parent charItae comparry to cease ta contlnue as a golng concwn. Evaluate the overall presentation. stnxture and content of the financial statements, Sncludlng the disclosures. and whetherthe financial statements represent the undertyln8 transactions and events in a manner that achieves falr presentation. Obtaln sufficient appropriate audit evidence regardine the financial inforniation of the entltles or business activitie5 within the youp to expre55 an opinion on the consolidated flnancial staternents. we.are responslble for the direction. Supervision and performance of the group au1t. We remakn solety resp)nsible for our audit report. We communlcate with those charged w5th governance regardin& among other matter5. the planned scope and tlmlng of the a•t and 5iznificant audit findings, indudin8 any significant deficiencies in internal control that we klentify during our audlL Explanat1 as to what exlent the was considered apable of detectlni Irrryularitie5• Includlng fraud Irregularitles. Includlng fraud. are Instances of non•compliance with laws and re8ulatlons. We design procedures In Ilne wlth our respI)n5ibilitie4 outlined above. to detert rnaterial rnisstatements In respect of IrreBularitie¥ includin8 fraud. The extent to which our procedures are capable of deterting irre8ularitie5. induding fraud is detsled below. The objectlves of our audit in respect of fraud. are: to Identh and assess the rfsks of material mlsstatement of the financial statements due to fraud: to obtain sufficnt appropriate audit evldence reeardin8 the assessed rlsks of matefial misstatement due to fraud, through de518nln8 and implementing approprlate responses to those assessed rlsks: and to respond appropriately to Instsnces of fraud or suspected fraud Ident5fd duriry the athlit. However. the primary responsibility for the preventlon and detection of fraud rests wlth both management and those charged with governance of the tharitabk cofflpany. Our approach was as follow&" We ¢>btsined an understandln8 of the le8al and regulatory requlrements applicable to the charitable company and consldered that the most slgnlficant are the Companies Act 2(Xl6, the Charltles and Trustse Investment (scotland) Act 2(X)5 (as amended). regulations 6 and 8 of the Charities Accounts (Scotland) RegulatKJns 26{aS amended), the Charities Art 2011, the Charity SORP. and UK financial reportin8 Standards as issued by the Flnanclal RepOn Councll and UK tax leglslatlon. We obtalned an undertanding of how the charftable company complie5 With these reqUireffnts by d15cSlOn5 with management and those charged with governance: We asse55ed the risk of material fflisstatement of the financ1* statements. Includlng the risk of material m15Statement due to fraud and how It might occur. by holding dlxusslon5 With mznasernent and those charged wfth Bovernance: We inquired of manoBement and those charged with 8ovemance as to any known Instance5 of non-compliance or suspected n(-CoMplIance with laws and regulations; 39
Independent Auditors Report to the Trustees of Gynaecology Cancer Research Fund Based on thi5 under5tandin& we de5i8ned specifK appropriate audit procedures to identlfy instance5 of non•compliance with Laws and re8ulations. This included makln8 enqulrles of management and those chr8ed with governance and obtsining additional corroborative evidence as requtred. There are inlkerent limitation5 in the audit procedures described above. We are le55 Ilkely to become aware of instances of nonrycompliance with laws and re8ulation5 that are not dosely related to events and transactions refiected in the finanaal statements. A150. the rfsk of not detecting a material mi55tatement due to fraud15 higher than the rlsk of not detecting one resulting from error, a5 fraud may Involve delllwate concealment by. for example. forgery or intentlonal mi5representatiun5. or throu8h collu5iOIK Use of our report Thls report Is made solely to the charitable comparfs rnefflbe. as a body. In accordance with Chapter 3 of Part 16 of the Companles Act 2006; and to the Charitys Trustee5, a5 a body. in accordance wlth 5ertlon 44(1}Ic) of the Charltles and Tntee Investment (Scotland) Art 2005. and In respect of the consolldated financlal statements. in accordance with Chapter 3 of Part 8 of the CharStles Act 2011. Our audlt work has been undertaken so that we rnight state to the charitable compan15 Thrnber5 and Tru5teesth95e matters which we are required to state to them in an alItaS report and for no olher pwpI. To the fullest extent perniitted by law. we do not accept or a55ume responsibility to any party otherthan the charltatAe company, the charltable companV$ members, as a body. and the Charirfs Truste a5 a body for our audit for th15 repor¢ or for the opinion we have fomied. James Saunder4 FCC (Sensor Statirtory AudStor) for and on behalf of Moore Klng5ton SmSth LLP. Statutory Au&itor 6th Floor 9 Appold Street London EC2A 2AP Date: Date.. 24 May 2024 Moore Kinaston Smith LLP is elighle to act as auditor in temis of Section 1212 of the Companles Act 40
Independent Auditors Report to the Trustees of GynaeGology Cancor Research Fund Consolidated Statement of Financial Actlvitles (Incorpordting an income and expendlture account) for the year ended 31 December 2023 Incom• Donaoon and legadas 915.249 325.958 1.241.205 1.514.513 87.W1 87.901 7&321 15.474 1 S.474 4.780 278 1.018.WQ 325, 1.344.858 1,597,614 Inv88tment Incorne Total Railing Fund 6.7J.10 8J.10 750 594.756 519.514 338.187 1.005.524 1.136.282 338.937 1,600,280 1.655,796 667.337 1261.343 Total Net IncoM•J¢ndlrn 1242,441) (1l981) 1255h221 I.1 2021 6.756 (6.758) Ptst ManI In fund• 1235.685) (19.737) (255A22) (5&182) Reconclllallon of Funds Total fillS brouw farnqrd 598.011 339.198 937.209 W391 Totsl funds Cath8d fonward 362.326 319.461 681.787 937,109 All the above amounts relate to wntinuin8 aaiitie& 41
Independent Auditors Report to the TNstees of Gynaecology Cancer Research Fund Consolldated and Charity Balance Sheet as at 31 DeGember 2023 Group 2023 Charfty 21)23 2022 2022 FI1 assets Inlanglbk IlyAd assets TaNJible flled assets InveBlment 15 3.461 17.] 7.431 28.173 3.461 17.981 7.432 1174 4.260 12,171 7.432 23I63 17 7.431 Currnnt Msels Stsxk 250 308.920 976099 1.286.069 191.1r25 928.89S 1,119.920 286.431 1.074.7 1,361388 180.863 841.477 1.022.340 Cash at bank and In hand Credllors: Amgunls falttng du• 467.1x16 447.941 N•t Currnnl A88•1• 652.914 913.347 567,284 881.787 864.992 Fynds 319.461 339,198 598.011 937,209 319,481 276.697 596.15B 339.198 525,794 B64992 Unrestrlcted funds Total Funds 681,787 As pwmllled by S408 rf the Cornponlts kl 21XI& the C(Thpany not wesentsd Its In¢m and expendlbjre slai¢ThJn related nL*e s bthotf Twnva Bo Chalr Comp•ny No. 4370087 42
Independent Audltors Report to the Trustees of Gynaecology Cancer Research Fund Consolidated Statement of Cash Flows for the year ended 31 December 2023 2023 C•8h flow8 from watlnq xllvlll (151012) 5.670 Cash flaws frnffl Inv•stlry adivbtles Interest Income Purchase of tangible fixed assets Purchase of intsn8ible red assets PurcPkise l acquisitlon of Investmen15 15.474 (9.384) (6.535) Ilet cash ud In In51£ ¥dl¥ltlqs (6,$35) Chan8e In cash and cash equivalents in the period Cath and c05h equiyèlents at l sanry 2023 I1722) 1.074.807 (683) 1,075, Cash arnl ewlvalents at Jl-Dtt43 928Ja5 1M74.607 ReCon(NL[on of net Incomellexpmdtur•) to net sh flow from Op9r1 actirhlties Net IncomeAexpen&rturp) forthe perfod Adjustments for. Investment Inccme Depreclatlon Amortkntk>n Decreaselllncrea5el In stock Decreaselllncreasel in debtors (0ecrea5e)fcreaSe in creditors .422) (58.1821 {15.474) 6.666 250 95hl 19,065 (76,238) 131.675 Net ash wg¥lded bylused lft opuatkn8 acthlths 5,670 of ush ush equivalents md net debts Cash in harKI and at bank Openln8 balance Cash41ow5 C105in8 balance 1.074.607 1,0752WJ 1145,722) {683> 28W5 1,074.607 43
Gynaecology Cancer Research Fund Notos to the Financial Statements For the Year Ended 31 December 2023 GENERAL k¥F(XIMATION cPanY knforrnlon Gymaecology Researth FWKI. operatkng as The Eve A, is o publlc benefft •nUty. a ch•rfty glstered In bolh England arKI Wales (f44ster ch8rfty number lo917) and S(y)Uand {SC0462612) nd 8 cunpany limiied by guar {o)mpw number 04371x187). regstwed In ErylaNI. The reglstered office and its piiropal place of Ix•lness15 The Eve AWMI. 11>18 Unlon Stree( Lond(. SE1 1SZ ACCOUNTING PIXICIES (al Basts of preprntlon The nlal 51atemqnts havo bow prrywed uThl8rtho listorlcal Msl cuNenllon with Ilerns rKogn at (mt or tren5action Val unless othwl4• stsd In the rdevant nole(s) to Ihw ffflancw stalemonts. The financlal slatements ve been prep8red in ac1018 ilh the Ac4xyJniiry and Reporung by Charili8s: Slalemerrt ol Reconvnended Prate applcable to Chath preparfng acMunt$ In adance the Flroncial Rep Standard appwcth In Iho UK and RepUbr of Ireland {FRS102) Indudlng Upd•ts Bulletin 2. {Charibes SORP (FRS 102). Ihe FI1CIal Reptyting Slandord apNo In the UK and RePliC of IrelwKI (FRS 102) and thè Companles Act 2LI Cancw Res6•¢h cMsOttrt¢s • publk ben8fit en •5 dofirnd ty FRS 102. Th8 finandal statts wepwed In sl•rflry. rhk18 the f¢41 enCY of the company. Mongtsry amounts kn these fin¢1 Slat1 •r• rounded to Ihe newes1 £1. Tho Tru51ees conslts Ihol IlwB aro rn rnthial uncartainllos atAwt lh8 gmup's akn7ty lo as 0 going concern. (b) Golnq Concorn The Trustees assessed wholhw of Wr¥J nCern Is apFropAato and have con$ldefed posslble events or conditsons that rnlght casl sigrarfit doubt on Ihe ablllty of Ihe group to ntInue as a ng cc¥Kem. The Trustees hav• giveft due consmleratlrm lo tho cunnl ernnomlc uncert2Tnty and havo Havlng revivd xBwls 1x8red by fflon8genwrt Ihe TnAes we cffiiiaent tho1 th8 CIMrKy and IJ group Cltinue kn meel Its o14Wih)ns as thoy fall duo and Ihat therefore goiry conBm b8518 con11n5 t> bo approwi Ic) Group Flnanclal Statofflents These finan¢kl $laternents consrfid•te Ihe res of Ctharfty Its omed subskllary. The Evo AP$1 nlad. em o lTn••4kn bfislj. Tha subslthary ajmpany h8s the end date of 31 Id) Fund Kcountlng Unre8lrfcled fvnds c(Nnptse aLrumSted aml ddclts on g8181 fvnds. They avall8Ne for usg at the diswol(m of the Trustees in fwth8r8 ol fv general Chatable obiKtsves. Desnated fu are urnstrlGtod lunds wNth we earmwked fty a Fw11lar purpose. Restrlcled fwcts are fvnds lo swdfic restjkllong Imposod ty lh8 dor& •) Incom• InGome rwresents 8Thun rKwvablv bylhe Charfty thri¥J Iho year from all %l¢e5. Al IrD)rne 15 Included tn ihe Ststement of Flnwxld A¢lth when Is legalyenlltled lo Ihe IrKome and Ihe no1 can i qwittf*d Tmlh rnasmalle arracy.
Gynaecology Cancer Research Fund Notes to the Financial Statements For the Year Ended 31 December 2023 Legaaes are accounted forwhen the Charity has entitlemrt receipt Is probable and the amount 1$ measurable. DonatlDn5 are aCcted for a receible l>asik Other tradln8 actNits are actourfÉed for on a recelvable basis and In the yarto whith they reknts. as%Klated wlth don•ted itern have been mel, tho receipt ol txonthc benefjt fr(xn ttiè use of lh& Charfty of the Ilem15 econ(xnk bendh bo mMsur•d rnw. fn Expendilure & VAT Eynditure is 9¢nted an basls arnl Is IKawl¥• of Tea>v•th VAT. Grants payable af8 ¢haryed lo Ihe Stslwnent of FtrwKlal Actlvltlas vAwi by th• Bowd of Charftable expendIrn c(xnpl$8s costs kKwred by Ihe Chority in tho defNeryoflts otyectrm. It Indudes both costs thal al0100 ¢lKe¢ty Io PAKh xttvllles and the costs of 1r8e1 88 necessary to supwt th Costs of ralslng funds Cwiprfse lundralslng cA)sts aTrd costs Inwrrnd In the sub$kary trading cfvitles. FundralslrvJ rnsts Include advatsiry. wodu(ing putdicabons. tIng arml malky fundral8lng m8teri8ls. 4%scclated slaff Lwts and an appwoprknts allocatlon of support cost& Suppcxl costs arn iIK>Be costs in9jN in rJUPPQrt ofthfr Ch•iYs piumry ab]8c and Orn akncat•d on the baskn ol stsff thm SFWt M IIK4e relevant aclfvlties. {9) T•nglbl• Flx•d AM•ts and thpmclotlon Depredakn Is pred all lblè fad assets kn rydor ts> Tlle off thelr cosl ty equal annval Instslrnants ovBr thelr expfdad useful The 8dor4•J Is u folkrA'. Flthres and'Fltllrys25% rn ajst (h) Inlanglbl• Flx•dAsgets and Amorton Inl8ngible Flxed assgts are rK(Yded at cost kn aM[w1kM iffwlmwnL Amryllsallonls wavkl8d (m dl TrJible fix1 a85ets kn onler lo vAito off Ihetr cost by annu Inst•lments mr 8xpecled uful Kves. Tho rth adopted Is as Tradema10 on cost (l) Invostmonts Unlisted Invesknenls ¢om tht foH¢y41w.- Imiestments In subsldlarles wNth are naswed at cost less Impalrn*nt Imiestments In aWnt ¥enture acquired in the year undef review. Under Ihe charity SORP Ihis is ffleaW using tho equity meltM)d flacc0wrwJ. The equity rnelhod of accounkng reqwes tho assoclats to knllalty r•cowised at Its c081 (tho transacllon prfce pald), Induthng any cost rnakiry the invesknent (tr4ns8ctM ¢ts}. Uslng th8 equlty method, the carn9 ¥mmI of Investrnenl In an asSotel8 sutseqwity a¢WBled through the SOFA to relled the In¥eth9 dw6trfs share of the a5%>cknte's results. The c8rryirvJ amwnl thereby reffecls tho Invesws shore ol Ihe posl •CYAson change kn net assets of thè 8ssodat•.
Gynaecology Cancer Research Fund Notes to the Financial Statements For the Year Ended 31 December 2023 U) StorAt St(Kk prkndpaty of armwk dtywted by artlsts and is valued atthe Imr ofcosl arnl rt feousable Va8. pred by 8rlts are wnl¥ed kn Ihe flnanclal slatemerts at thelr anthPalad so1•8 (k) Cuh and cuh •qulvalents CB8h 81 bank and Tri IHnd incKles thvknich can be 24 I1$ llhoul p•nalty and short.t•rni deposts a mattirity perfod of 3 monts or less and aro T1 subject lo siwificant rf5k of changes In value. (l) Tax Sl•tu• G88clO9Y Cancer Research Fund (Limknl ty ?¢•) Is a l$ted company. number 04370087 arKI 1$ exempt from tax under Ihe PTovtslons of Seckns 466493 af tha Corporntmin Taxes Act 2010. (m) Ow4rntlng L•JH Rentals payablo undur DPBT8ffnB18zs arn chaw to the Staknrt ol Flnwdal AcOvlle5 as kK¥Jrnd ¢)ver the ol Ihe lease ¢Jn a StraIght4 basls. In) Penshns The Chwlty opwakns a contrlxthon penslon 8themo. Th• cryfyil)uli(ms to the defined contrlbuuon (o) Flnanclal IR3truments Tn• Charfty only hag ènanthl assets and IkwKial labllt185 of a v1 qu811fy Js ba flnanclal In8trumvJnts. Baslc fina81 instrWts arn knlllalty >1$e0 ot transactton ¥8 and subsequwty sured at thelr setlern ¥. Th• Clwlyd(ws nDI have w b loan& Ipl 31gnllle•nl Aceountlry E8tlmth and Judgomerts Eslmates arNI Judgements are CO1 rnkwt•d arnl arn basad onl1810 eNlenrn arml OL factors, inCg eweclallom of I1 e4nls tho1 we bell•4d > be reasomtrje wder th• GI In klnd Gift8 in k6 we recoonised thIn re8ouvrns and eyxllwe al an estlmate of tr valu• lo Charfty of the donaled servkes or ad$. Wharn p>88QJlo th• va& (rf Sce$l90cIdS aro confirmed dlrecty wtth the suppller IMYd¥evw in %>m• inslaKes wrformal(x) is 4Wt avaltable and a best estimet•d 1$ mado of the expected cost of such bosed the Ch Y>ukl be llIng b pay for similar 6eThlces or goods at o m3rk•l r•ts. Vb) Grnnt ¢r•dltorn In the y7ar ended 3W06rao19 tho Tnth8s ¢Thldered Ihe Ire81M rf tho recc•3nllon ofgrwrt rndiiors faIrj due ltNn one year arml af•rorn year and h•v• athptffil a better esfjmat1( of crEditQFS IBllry dua within one . As a we5uIL a wlor year aluslment was r815ed In Ihe ended J1106r2018 to th8 bi treatrnent of Ihe cornparatNo5 cvrrenl y.
Gynaecology Cancer Research Fund For the year ended 31 DeGembor 2023 J. In¢omo4>onotlon and Lagxles Umlcled givkng Communlty Tw8ts and fwidatlons Mar dono Coor8 Legacies Gifts In lfjnd 328.189 39. 358.871 5A08 237.71XJ 14100 37,671 19,OCrf 108,278 55.870 114,626 334.157 3]928 11292 21871 89.278 55.870 114.626 266.761 91.598 51.030 202.$26 214A93 &249 325,9 1.241205 1 $14 513 In 2023 £880.85512022: £1,1363821 ol don•Uon$ and l•q•rlo8 r•lal•d to unrn5trlCt fund• •iid £325.956 (2022: £378.2311 wa$ attrfbutabl• to restrlct•d fund& In¢•nw from dgnatlonB and i In¢lude¥ donated Serv1 worth £T7501202* £214A93). 4. Inrne- Inwn• From Trndlng Acl1¥ 2022 R•strlct•d Cofflr 6,104 Trad subslthary (s•• note 17) 87.901 87,901 87.901 T2,217 78,321 47
Gynaecology Cancer Research Fund For the year ended 31 December 2023 & ANALYSIS OF EXPENDrrui Dlr•¢t Co•1 Totsl 2023 Expendlture on ral8ln9 (Nole 6 and 7) Expandire on chorftabla athioes (Note8) Chwity Eyndltw• an raislng Consolidated 495A88 80.336 850.379 126.894 1.345.967 207.230 967 207330 18.832 4.756 28.249 1,005.522 47.081 1.600278 47 081 1,600371 Dlv•¢t C08t &Pt G•)bTrnance Cost Cosls 404.461 91347 16.706 519.514 B63.376 147.846 25.060 1,136,282 1.367.&37 246.193 41,766 1,655,796 1367,837 246.193 41.766 1655 796 Total 2022 Eyndltur• M raL8kng fimds (noto$ 6 7) Expendllure on charltable athils 8) Charfty Expendllurn on rthg fund8 Consdktr EandIre relaung b ral8lNJ funds kn 2023 m £594,fA16 wreslrklad1%122: £517.818) and £751 rostricled (2022: £1.696). Exwndilurn on tharftablo 8clMllas In 2023 was £667.336 unrgstrithd {21Y22". £732,476) Includlrwj (l8t0d sart•s **rth £114.626 (2022 £214.493) £338.186 frnm restrktad (2022: £403.806).
Gynaecology Cancer Research Fund For the year endod 31 December 2023 J. DIREcf COST8 OF GENERATING DONATIONS AIID LEGAC 2023 48.183 73,112 3.264 727 381 18.152 353,768 IndMthJal gl¥w cnmUnIty Legad•s TNsts and fwndalon5 Molor dono Corpuate 47,870 72.777 313 41,628 89,744 4,891 3.941 7.123 249,149 279 16.152 353.768 102 750 391476 7. DIRECT COSTS OF TRADING ACTiinTES 2023 2022 7.985 Cornnwnlly TOTAL IXRECT COSTS OF RAISING FUNI)S 495,587 404A61 Al staff c¢>sts (Incl119 5*188) relthg kn txroct Costs of Ratslry have tse alIlad th[8 year to Central cr4ts 8). 8. DIRECT cosrs OF CHARITABLE ACTMTIES 2023 248.861 76.776 182.275 232.151 2022 367.492 Researth grants (note 11) Ask Eve. Nurs&Led Infmellon EWP-DHSC Informall & Awarene Research Glft¥ kn ki 152,528 96.333 38.204 38,572 (344) 182.619 217.870 14.281 303,788 61.349 518.576 331805 81,349 214.493 963,376
Gynxcology Cancer Research Fund For the year ended 31 December 2023 g. DIRECT COSTS OF GOVERIIAMCE 2023 16,679 2022 14.629 Group. Audlt laes Grcup - Non audll le tXrector8 Indemnty Insurance Insurance Trvstee cosls stoff and contractor costs 11679 1.157 1.157 275 972 25.501 72 27.738 47M81 47.081 41.766 10. ANALYSIS OF SUPPORT COSTS 2022 18,994 2,883 40,476 127,178 36,876 19,6 Ronl servlce charge and ubTtses Insuran IT. One arKI knternet Staff and witractor ctr4ts 11.961 13.844 31.122 139282 18JeO 4.123 35,245 139,282 18,753 193 Resea adnun15trallon 200 207,230 246.193
Gynaecology Cancer Research Fund For the year ended 31 DerAmber 2023 11. RESEARCH GRANTS AWARDED BY114STmiTK>M Included In Charltsble ActlvFtJu wtre the follow1 research 8rant&' 2023 167,028 2022 188.405 90,(¥JO 87.262 1,825 160393 Vi¥8r3{fy ol Blmilngharn Grnnt rod•rnl 89.700 89.7(XJ (7.866) 152 333 248,860 11 sTF COSTS 2023 721927 89.81P 27,653 820.399 Wages ond so18rle 505.594 51.271 18.614 575A79 136,335 711814 Staff perni1 Cost of contrac18 The Thmnberofefflplayws vthose tolal onWo>e boneffts (eXthl emplo98 colts omplw natknal 2023 £60.000. £69.999 £70m). £79.999 £80.(XK1. £89,999 £90.CrfJO- £99.999 11 10 Fundraisww supwl 16 Tho key m8WrnMt pernanrrnl of the pat thwity comprtses Ihe Tntstoes. Chlof Exeuthe, the Dlractor of Fundr8lslng, the Head of Pwramrnes and ts Head of FlnwKe. The IA>tal emkne beneffts ot Ihe koy mawnt pernonnol kn Ihe •r• £2TT,417 £219.91r2 13. TRUSTEES. RE&1UNEIIATION AND EXPENSE3 OR BENEFITS111 KIMD None ofthe TnAtaes rec4i4Yd Y remurwallm dwlry ts sTor (2022: rn>ne Ihfr J•8f £1.1S7 2. £W) was POMI in raeCt of Tr180$ Indemnlty Inww No Tntaos ¢laimed for durfrrtj ts yw (2021. n? NEf MOVEMEKf IM FUND8 2023 2022 Ngt rnrnmerrt kn funds Is stated aftw ¢harylrrfJ: 15A79 799 8.011 16.704 Deweciation AThKwnts pable under r•ernfjng Iwes: Land and &lldh4s 4&765 57,440 51
Gynaecology Cancer Research Fund For tho year ended 31 Decombgr 2023 15. INTANGIBLE FIXEO ASSETS- Graup and Clw Amorlhalkn At 1 January 2023 Amortls8lton Al 31 Decernhr 2U23 3.728 Net book v¥kM at 31 DKembor 21r23 Not book vafuo at 31 Decemlxr 2W22 1& T•nglbl• Flx•d and Equlpm•nt C•91 At l January 2023 Addillons ISpO&15 103,654 1& Deprnclation At 1 January 2023 Ch¥ryo ftx tha yèAr 87 &011 N•1 Book V•lu• Al 31 Decen*w 2023 At 31 OKernber 2022
Gynaecology Cancer Research Fund For the yoar ended 310ecembor 2023 17. INVESTMENT8 HELD A8 FIXED ASSETS . Charlty 2022 Shpres kn &b8kllw Undertaklnp at (xmt Shorn5 kn Jolrt venr¢ wl Ivo 7.431 7A31 JoIntVanr• Tho CPwlty ho8 a 8h•rn In Sda tWoJlcJ GfflB $11n Shvas will thuease ov T1 con9 ofthB Investrnent was £7A31 •t li do8m•d kn bo Hs vAIu•. Subsldlary through acli¥tty Inctudtry cause rnlat•d mathdry and sths ofgoth. Th• rnnygny parJ its undw Glft Atd lo the Gyffaal¢al Cgncer Resth F Profit and Loa• Tumover 2023 87.800 1270 14630 2022 73.W2 875 72.217 NW wofft before lax Ta Nel rns •4030 72.217 Profll and r•s•rv• 6nght ftwwonl 81 l JaNary Net result in pvrnd D16tribultffj lo G>Trecokw Reseath Furnl 72,217 85.630 2.217 85.630 26,653 72217 .653 72.217 Summvy Balan¢¢ SI Cury•nt Au•t• Debt1 Cash at bk and li h•KI Z8,339 87.420 115.759 273 CuTh•nt Iljbllttles Crndilor5- amDunts due *llhlTr cm Net 4wrent assets Total assets tot81 Xi.129 85.630 25.764 72,218 Capltal and rns•ThTs Shorn captsi Profft •nd101s •K¢xmts 85.630 72,217 72,218
Gymaecology Cancer Research Fund For the year end 31 Drt•mber 2023 18. DEBTORS Gnwp 2•23 5.898 18.181 271J140 146,163 7.818 10.623 2022 7,500 22.763 271,040 7.617 146.163 10M23 othor debtors 191.025 28eA31 110.863 19. CREDrroRS Grn Charfty 2023 418.838 15M31 20,450 2023 388,W8 418.838 9.021 15.250 Grnnts payable Trnd8 Credittys 16,919 6235 1.645 13.919 5,109 2,770 0th8r Crnditty¥ 11.927 117 447.941 20. UNRESTRIMD FUND5- GROUP A131 DaMb•r 2a23 182.326 180,000 Genwal fvnd6 Ernaryency fund 418,011 1.000 1.018,902 (128lJ43) 11 11.902 1.261.343 756 326 Ern•ry•w Furnl The reMbvas pollcy fcrthe ¢harity. 05 ogreed by tho is to o mlnlnwm ¥vag Th)rrtl buled expendrn. eXling on rnsearch F11 thkn and th8 ralirmth lor this can bo fwrNI tho reser¥es seclian of1 Trustee Rewt Tr4nthrn UNRE8TRICTED FU14DS- CHARITY At31 DKernber 2023 96,VJ7 180.1100 At Jawary Ine•rn• Exp•ndknrn Tr•n¥fers <1261.343) 8,756 G•neral fundg Emyncy fund 344794 10OMOO 525.794 1.005.490
Gynaecology Cancer Research Fund For the year •nded 31 Doc•rnber 2023 21. RESTRICTED FUIIDS- CHAVfYD GROUP •aJanuary D•¢•mb 2Q23 11&162 (38.158) 175.004) Smal Cell Cancers RCA Proled BReA Resean Cornputotional B¥JoBy 6,633 1<104 16,633) 1499$ 11250) 1857) 7&013 Vulval Conc•r Awarenes8 Know Your W (f knrMI as Evory Glrf Promlso) 872 2.081 78. leamlng Vuhal C4nrnr Exlensljn of Ask E¥0. 349 (6.3491 Res88ffh 4Q567 (TI) I683> .107 Lyn¢h Sy¥Jrom• Guido UCL Strairyc Res•a Funding E¥eryWmn PwoTh¥ 10,51KI 8083 12.750 12•.701 126.709 (189A4) 16.881 don C•ncw A - Won Cancer Awarw Ourtroa¢h 16.756) 11.413) 18,587 Vulval RIBk Pred&Xlon 89.700 750 32S956 TIWfern acliwly fopjssed Im same wth8nce UCL slrateglc roSrth progfamrn• Tho Vulval Cam PXKawJ•d th8 fiffMl• n¥Md lo tho G0? Fund th•r•
Gynaecology Cancer Research Fund For tho year ended 31 December 2023 Regtrkt•d Fundi Is underslandkng tt¥Jse gruup5 TAkn carrynKrtd genfr$ doaP The. BRCA R4i••rth: Severdl of our re5¢wth kYogrnmm8s hava a strang 10(w3 an tho BRCA ggno mulaU¢)n to earty detect or pr¢vOntOVWi ab Inasl formpla BRCA PROTECT. BRCA UNITE and GCaPPS. Computatlonal Blology T•1. Our wogranrn requiy a substs (xMnpthll(ma b, BtsdsttC8 and b Infomthcs thlth are central to our rnsearth. Vulval Cmur. Vulval eancgr ts Oltho rnrnr IY4Kxrs T1 ovor 1.IM)O cases In the UK dla9nwd 88ch >wr. lnerna awareness otthe and S1m$ ofvul¥al Ca arn essenU31 lo en8W• I wamon so9 th8tr GP 09 soon as they not1 not light fty #wn arrfl lo keep golng back rfit aNnd e¢tstn rnpOan3 as Gel Bl••thry Clrknd. •Learnlng Vuhal C8nc•r Th115 the wbsi Imfjngtr tho Royal College of GPS Know Body Ifonrnrty know as Ev•ry Glrl fimd ts an othath sYogranMM lo th 4•ilh chools aboul ge¢1 hèalth. This15 fi¥wJed by ICAP Iwt has be by tho globBI pandemic. HPV Re>Qu. Th$ Tmorks ID •mbod a deeper •nd morn nuan¢ad pubk underslanding of HPV. HPV and rolated aty(m the IxJ¥rd. Ext•n$lon of Ask E- South Aslm Communlths.. TIDd Inf0mlI1 and ci>mnwnity •ducatk ts Imwè gJwecoSJglcat heallh rJJtThs. The evaluate and addrnss Iho naeds ol Ihre8 key Ilare GVIo91CaI C¥nur L•ss thon S% ol the 21.IXX) d8gn05ed th gsrywecological cancer in the UK aro dligrnsed a rwo forni. Th• wfflljer ol new cases Ih8se rnrerconws mean IrNli¥lUl doctws pJe vnfamllar ¥Ath t< oft•) rasuliry In 4 late dlagrw, tr08lrnnt Ihat m not be opkn81 for tha dlsease type subsequ1 prngRSSiL ol dis@as8. More is noled to Ovarlan C•n¢er Res•aTch: kn th¢ UK nrfY 7500 PBopl8 ar• ifiawsad wtth ryéarfan •very >•ar. Th• are not always obVMX. and it is diagnosqd In a Lqkn s•. RaBaath deC risk wedicfjon •nd prwenkn Is neaiknL UCL Strategk Regewth Fundkng: fow¥in9 Prol MIsdyS res•arch cTrtrNlng at UCL Thè (nICal A6se89menl & Work up ol tho WDqEC Past at Ngh Endorntrlal (Womb)Con¢w. Ev•ry Woman Promlse: Thls wo]ecl supports aThJ t¢S Il lo rnport snpln$ and 8eokG advre on gyna•I09l health15syes nmkes emplry*WS ware of i5SU8& ThB aim is to both Imprm Ih? heolth rJw)e8s for eath but also lo lrryjl the coryx>rate envFronffenL through
Gynaecology Cancer Research Fund For tho year onded 31 Docembar 2023 IIE London Canr AHlane•. W£¥nb T•ith the NHS io dthar 12 awarnn885 anmgst womthx PToJe(a MIlY forui ¢Jn areJB thern18 a larp 81•d( Afrkan. Black Carfbbean or Soulh Aswn pcwl•¥w bjl ¥AI t• tr)all r4n8n rngard¢s$ of th, sexu Outreath: Thls fund ts Out Ir wlbound and lfid as yrtofA Éve. VLlnl Alsk PredkthwK TNS fvnd 15 fort rt15 1 new researth woJocL More () cBn bo In the p•9• 13 arnl w the Ask s8Thira on pap 16 af TNsle• R 22. LYSIs OF IIET ASSET5 BEfwEEN FUNDS- GROUP Fwrtls Funds Tatsl 20ZJ T(thl al22 28,8n 23,862 319A61 1.119.9a) 1.361.288 (467.006) (447.941) 81X>.459 (487.1N) CrndloffL" amnts IAlh¥ duo th 1 >eor 361326 319.461 e11.787 937.209 23.LEGAL 8TATU8 OF THE CHTry Th8 Charity 15 Inwt•d by guarantee and Ihernf(n doe5 not hav• a shore ¢aW. Th• l•oftho memlxrn18 knmted lo th• surn of £1 pgr n)kn. and Ilw wrnbof was 14 (2022.13 XULTThIATe CONTROLUKG PARTY Eve Appeal Lknited ts aAtholty sub dGrncy C•nc•r F. whlch IJ tho uIUrnal• GU01al lled kn tha p•ficAI, lrtludkq pwtrws12021' £31298 from 15 Trust ¥KlwJng pathrnj. R••d LLP Jyo btsrn> legal ser¥1& lo • dwtyin th• arlOt? £14889.35 (20?. £70.1381. Tamarn Is Reed Smth LLP b alw • ultho ¢l&q. 26KOIAMITIIENTS UNDER OPERATING LEASES Gro Charfty 2022 X23 2022 WilFin on8 > 8ehv8en >Tar •yl fvo Alter fivo years 1Q675 10.675 42.700 10.875 38,OKI 10.875 42,700 4.065 57.440 46,765 57.4140